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Cancer continues to be a highly prevalent and lethal disease, despite 
significant advances in understanding tumor biology and developing new 
chemotherapies. Major obstacles in cancer chemotherapy are drug resistance 
and systemic toxicities. Potential strategies for addressing these problems 
include delivering combination therapies to overcome drug resistance, and 
utilizing synergistic agents to minimize dosing and subsequently drug toxicity. In 
turn, delivery can also be optimized to target the tumor site and consequently 
minimize systemic side effects. Polymer nanocarriers are gaining interest as 
vehicles for cancer therapeutics for their abilities to not only deliver multiple 
agents, but also target the tumor itself. Our goal is to design multi-layered 
polymer nanoparticles (MLNPs) for efficient delivery of small molecules and 
genetic material towards synergistically inhibiting tumor growth. The MLNPs were 
first optimized for transfection in vitro through delivery of plasmids encoding for 
luciferase (pLuc) and green fluorescent protein (pGFP). The particles were then 
evaluated for effective delivery of both a candidate small molecule, camptothecin 
(CPT), and a plasmid encoding for TNF related apoptosis inducing ligand 
(pTRAIL) (CT MLNPs). Co-delivery of CPT and pTRAIL via CT MLNPs were then 
evaluated for growth inhibition of brain, colorectal, and breast cancer cells in 
vitro. MLNPs were approximately 116 nm in diameter. They were able to delivery 
approximately 575 ng of plasmid per mg of particle, and between 0.1 mg to 0.01 
µg of CPT per mg of particle. MLNPs were non-toxic, and human embryonic 
kidney cells (293T) transfected with pLuc loaded MLNPs expressed comparable 
amounts of luciferase as cells transfected with the gold standard lipid formulation, 
Lipofectamine 2000. Thirty-seven percent of transfected 293T cells expressed 
GFP 72 h after transfection. Studies on tumor death kinetics related to CPT 
exposure and pTRAIL transfection suggested that simultaneous transfection and 
drug exposure provided the greatest inhibition of cell growth. MLNPs were able 
to provide the optimal timing for delivery of both agents. Synergy analysis of co-
delivering CPT and pTRAIL via CT MLNPs, using the Chou-Talalay method, 
provided a combination index at 50% inhibition ranging between 0.31 and 0.53 
for all cell lines. These CI values indicate a synergistic interaction between the 
two agents. For obtaining a 50% effect level, co-delivery with MLNPs resulted in 
providing 3.14-7.38 fold reduction in CPT and 4.66 to 6.09 fold reduction in 
pTRAIL. These initial results support our hypothesis that MLNPs can deliver both 
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1.1 History of advancements in cancer therapy. 
The oldest documented case of cancer occurred in Egypt around 3000 BC. 
The record details eight cases of tumors involving the breasts, and ominously 
describes the disease as having no treatment1. Although surgical resections 
have been utilized since 1600 BC as a treatment modality, it was only in the mid 
nineteenth century, with the advent of anesthesia, that modern tumor resections 
were utilized for cancer therapy. The improved techniques allowed for more facile 
resections and better outcomes. Emil Grubbe, a Chicago medical student, first 
used X-rays to kill cancer cells in 1896. Surgical and radiotherapy continued to 
be the mainstay of treatment until 1948 when Sidney Faber, a pathologist in 
Boston, used an antifolate compound in children with leukemia2,3. Farber was 
able to induce remission, although transient, in his first patient, and consequently 
pioneered the field of cancer chemotherapy.  
The ensuing decades have since generated numerous advances in cancer 
biology and chemotherapy. The evaluation of the biochemical processes involved 
in drug resistance made considerable strides in the 1960s, and resulted in the 
implementation of combination chemotherapies in 1965 and adjuvant 
chemotherapy in 19723. The National Cancer Institute began increasing support 
of molecular cancer biology in the 1970s and 1980s, which was rewarded by the 
discovery of the first oncogenes in humans in 1976 and the identification of the 
critical role of TP53 in cancer development in 19894,5. Significant improvements 
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in cancer mortality were first noticeable in the 1990s, and the field of targeted 
cancer therapies blossomed with new discoveries in cancer signaling pathways 
involved in tumor development, proliferation, and metastasis. Identification of 
novel targets enabled the discovery of targeted therapies including Imatinib, a 
tyrosine kinase inhibitor, in 1992, and Trastuzumab, a targeted monoclonal 
antibodies for HER2 positive breast cancer in 19983.   
Further, the completion of the Human Genome Project in 2003, a historical 
point in the field of genetics and overall scientific exploration, allowed for 
revolutionary advances in understanding many human diseases including 
cancer. Multiple international projects, like The Cancer Genome Atlas, were 
initiated to analyze the genetics of multiple cancer subtypes. Through extensive 
genome analysis of tissues from several patients, researchers are gaining a 
stronger understanding of the development, susceptibilities, and prognosis of 
individual cancers, and in turn learning how to design patient specific therapies. 
Consequently, the death rates for common cancers, like prostate, breast, lung, 
and colorectal, continue to decline with the development of new small molecules 
and immunotherapies, target specific screens, and novel combination therapies. 
In 2003, the five year survival for cancers from all sites has increased to 66.7 
percent. Despite these promising advances in cancer therapy, it is still the 
second leading cause of death in the United States. There are over 1.6 million 
new cases annually, and approximately 580,000 deaths each year6. These 
numbers will likely increase due to the continued aging of the population. Even 
as cancer survivors live longer, they are at a higher risk for developing new 
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malignancies. Further, the issue of drug resistance and tumor recurrence 
continue to hinder cancer therapies, and more investigation is required to 
overcome these obstacles. 
1.2 Cancer biology, drug resistance, and rational therapeutic design. 
The birth of scientific oncology ensued when Rudolf Virchow examined 
blood samples from leukemia patients under the microscope in 1847. Currently, 
cancer pathogenesis is considered a complex multistep process where cells 
attain certain hallmark properties through both genetic and epigenetic 
alterations7,8. Carcinogenesis is primarily a consequence of changes in the 
genetic code or gene expression. The affected genes can be categorized into 
three main groups: oncogenes, tumor suppressor genes, and mismatch-repair 
genes. Changes in gene expression may in turn allow cells to maintain 
proliferative signaling, evade growth suppressive signals, resist cell death, 
promote invasion and metastasis, confer replicative immortality, deregulate 
cellular energetics, promote genomic instability, and initiate angiogenesis9.  
Additionally, tumor interactions with adjacent stroma and the immune system can 
promote proliferation and metastasis through avoiding immune destruction and 
stimulating tumorigenic inflammation. The multiple, interconnected pathways 
complicates efforts for providing effective therapies. Therefore, a paradigm shift 
is underway as researchers are working to analyze individual tumors in order to 
design therapies for specific cancer phenotypes.  
Additionally, epigenetic factors can promote carcinogenesis without directly 
conferring any genotypic variations. Deoxyribonucleic acid (DNA) methylation, 
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histone modification, and gene silencing are interesting epigenetic events 
involved in cancer pathogenesis10. New therapies have been produced to modify 
histone acetylation, which can consequently alter gene expression11. Further, the 
field of the RNA interference (RNAi), through small interfering RNAs (siRNA) or 
microRNAs (miRNA) delivery, has expanded significantly, and can potentially be 
utilized to silence any gene of interest12,13.  
Evaluating the steps involved in cancer pathogenesis has in turn allowed for 
the development of more effective therapies. For instance, cancer cells can 
develop increased proliferative signaling by up-regulating surface growth factor 
receptors like EGFR. Researchers have translated these discoveries into 
promising clinical therapies by developing EGFR specific inhibitors. Similarly, by 
analyzing the specific hallmarks necessary for cancer progression, new pipelines 
of therapeutics are being developed to treat the disease. Table 1 describes the 
multiple hallmarks of cancer pathogenesis, respective cellular and molecular 
alterations, and associated targeted therapies7,14,15. Through extensive molecular 
and genetic analysis, physicians are better equipped to detect, classify, monitor, 
and ultimately treat cancer. However, the difficulty in designing adequate 
therapies is becoming increasingly clear as we begin to understand the 





Table 1: Hallmarks of cancer pathogenesis and therapeutic 
implications7,14,15. 
HALLMARK OF CANCER 
PATHOGENESIS 







↑ MAP-kinase pathway, ↑ PI3-kinase 
pathway, ↓ PTEN, mTOR kinase pathway 
EGFR inhibitors 
2. EVADING GROWTH 
SUPPRESSORS 




3. AVOIDING IMMUNE 
DESTRUCTION 
↓ CTLs, ↓ CD4+ Th1 cells, ↓ NK cells, ↑ 
Tregs, ↑ MDSCs, TGF-β signaling 
Immune activating 
anti-CTLA4 mAb, 





↑ Telomerase, ↓ TP53 Telomerase 
inhibitors 
5. TUMOR PROMOTING 
INFLAMMATION 
B lymphocytes, macrophages, mast cells, 
myeloids progenitors, necrosis, 
neutrophils, T lymphocytes, ↑ IL-1α, ↑ 






↑ CCL5/RANTES, ↑ c-Met, ↑ CSF1, ↑ 
CCPs, ↑ heparanase, ↑ EMT, ↑ IL-4, ↑ 
matrix-degrading enzymes, ↑ N-cadherin, 
↑ Wnt signaling, ↓ E-cadherin, Snail, Slug, 
TGF-β signaling, Twist, Zeb1/2, 







↑ FGF family proteins, ↑ Ras, ↑ Myc, ↑ 
VEGFa, ↓ endostatin, ↓ plasmin, TGF-β 
signaling, ↓ TSP-1, endothelial cells 
Inhibitors of VEGF 
signaling 
8. GENOME INSTABILITY 
AND MUTATION 
↓ BRCA, ↓ TP53 PARP inhibitors 
9. RESISTING CELL 
DEATH 
↑ A1, ↑ Bcl-2, ↑ Bcl-xL, ↑ Bcl-w, ↑ Mcl-1, ↑ 
extrinsic growth factor signaling, ↓ Bax, ↓ 
Bak, ↓ BH3 proteins, ↓ TP53, ↓ extrinsic 















Cancer stem cells, endothelial cells (notch, 
neuropilin, Robo, and Eph-A/B singaling), 
fibroblasts, myofibroblasts, neoplastic 





Bax - Bcl-2-associated X, Bcl - B-cell lymphoma, BRCA – breast cancer, CCL5/RANTES - 
Chemokine (C-C motif) ligand 5/ regulated on activation, normal T cell expressed and secreted, 
CCPs - cysteine cathepsin proteases, CD4 – cluster of differentiation 4, CSF – colony-stimulating 
factor, CTL - CD8+ cytotoxic T lymphocytes, EMT - epithelial-mesenchymal transition, EPH – 
ephrin type, FGF - fibroblast growth factor, GLUT – glucose transporter, HGF – hepatocyte 
growth factor, HIF – hypoxia-inducible factor, IDH - isocitrate dehydrogenase, IL – interleukin, 
LKB1 – liver kinase B1, MAP – mitogen-activated protein, MCL – myeloid cell leukemia, MDSCs - 
myeloid-derived suppressor cells, mTOR – mammalian target of rapamycin, NF2 – neurofibromin 
2 (merlin), NK – natural killer, PI3 - Phosphatidylinositide 3, PTEN – phosphatase and tensin 
homolog, RB – retinoblastoma, Robo – roundabout, TGF – transforming growth factor, Th – T 
helper, Tregs - regulatory T cells, TSP – thrombospondin, VEGF – vascular endothelial growth 
factor, ZEB - Zinc finger E-box-binding homeobox.  
 
 Despite our increasing knowledge of cancer pathogenesis, the disease 
process remains extremely complex. Every cell lineage in the body can be 
affected. Inherent genomic instability and biological diversity in cancer cells can 
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lead to treatment resistance. Only a small fraction of tumor cells is highly 
sensitive to therapy, and even they can develop resistance and progress into a 
more aggressive disease. Drug resistance can be either intrinsic or acquired. 
Intrinsic resistance describes tumor cells that have decreased or no sensitivity to 
therapeutic agents. Cells can develop resistance through a variety of 
mechanisms including decreased drug uptake, up-regulation of drug efflux 
transporters, aberrant cell cycle checkpoints, increase in DNA repair, increased 
drug metabolism, induction of stress response genes, and inhibition of 
apoptosis16. Additionally, individual cells can be resistant through its own unique 
variation, which further complicates cancer therapies. Acquired resistance refers 
to neoplasms that were initially responsive to certain therapies becoming 
unresponsive. Similar to the development of bacterial resistance to antibiotics, 
chemotherapeutics can select for inherently resistant tumor cells. Due to the 
characteristic genomic instability of many cancer subtypes and the mutagenic 
properties of chemotherapeutic interventions, new mutations can readily lead to 
the development of drug resistance. Of note, hierarchies in signaling cascades 
involved in tumor development, can diminish efficacy of targeted therapies, if the 
new mutation overrides the targeted factor in the signaling cascade. For 
instance, mutations in the tumor suppressor gene, PTEN, can decrease efficacy 
of anti-HER2 immunotherapy, or inactivation of TP53 can minimize the 
cytotoxicity of several cancer therapies17. Mutations and natural selection are 
fundamental in the development of resistance, as they are the primary drivers of 
cancer pathogenesis.  
8 
 
 The two overarching models of carcinogenesis are the stochastic clonal 
evolution model and the hierarchal cancer stem cell model18. The original 
stochastic model describes tumor pathogenesis as the progression of somatic 
mutations that lead to isolation of a dominant cancerous clone that, through 
selective influences, eventually progresses into metastatic tumors. However, 
during the past two decades, studies have shown that certain cancer types arise 
from a more hierarchal organization of cells. These tumors are comprised of 
multiple cell subpopulations having a spectrum of proliferative and regenerative 
capabilities. Bonnet and Dick first described this phenomenon in human acute 
myeloid leukemia cells19. They isolated rare leukemia initiating cells that have 
differentiate and proliferative capabilities similar to leukemic stem cells, and 
demonstrated that these cells are responsible for the regenerative, self-
perpetuating, and diverse nature of the tumor. The primitive tumor initiating cells 
are inherently quiescent and less susceptible to traditional therapeutics that 
target rapidly proliferating tumor cells18,20. Subsequent studies have identified 
tumor initiating cells in breast cancer21,22, colon cancer23-25, melanoma26, and 
brain cancer27-29. Therefore, effective therapies will require targeting of these rare 
initiating cells since traditional chemotherapies target only the proliferative subset 
of the cancer. 
In addition to tumor biology, multiple host factors influence efficacy of 
current chemotherapies. Decreased absorption, rapid metabolism, and increased 
clearance can decrease serum drug concentrations. Delivery to the tumor can be 
impaired in large, necrotic malignancies. Additionally, drug solubility and size can 
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also hinder tumor delivery and penetration. The tumor microenvironment, 
including both the abnormal vasculature and adjacent stromal cells, can impede 
drug delivery or increase drug clearance. Patients also have variable capacities 
to tolerate chemotherapeutics, and the development of certain side effects can 
significantly obstruct dosing and treatment duration16.  
1.3 Strategies to improve cancer therapies and implications in personalized 
medicine. 
With the discovery of numerous clinically relevant cancer genes, new efforts 
are being implemented to streamline evaluation of cancer genomes towards 
ultimately translating to personalized, clinical therapies 30. Improvements in 
sequencing technologies have evolved into new paradigms for analyzing tumor 
specimens. Massively parallel screens can examine patient samples for 
potentially actionable targets30-32. Further, a pilot program, the Master Protocol, 
was recently approved by the Food and Drug Administration (FDA), and will 
connect patients to relevant drug therapy trials based on biomarkers33. 
Determining specific gene or biomarker expression profiles can align specific 
disease with the ideal, patient centered treatment regimen.  
Due to tumor heterogeneity and the development of drug resistance, future 
therapeutic regimens will likely incorporate combination therapies. Bozic et al. 
described a mathematical model that evaluates tumor response to targeted 
monotherapy and combination therapies34. Dual therapy was often adequate for 
long-term disease control, and patients with a larger initial disease burden may 
require triple therapy. Additionally, simultaneous therapy was more effective than 
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sequential therapy. As the spectrum of genomic targets or abnormal signaling 
cascades widens, it is becoming increasingly difficult to develop targeted small 
molecules or immunotherapies. Gene therapy can potentially address that issue, 
since it has the potential to alter expression of any gene of interest. However, 
gene delivery can be either inefficient or dangerous. Similarly, the multiple 
clinically available chemotherapeutics are highly toxic, especially with systemic 
delivery. Commonly used cytotoxic agents can act indiscriminately against both 
cancerous and healthy cells resulting in nausea and hair loss to more serious 
toxicities, including neutropenia, peripheral neuropathies, kidney failure, 
encephalopathy, and heart disease35.  The associated side effects of common 
chemotherapeutics, as well as host factors and systemic delivery barriers can 
severely limit dosing and, ultimately, treatment efficacy. Current research in 
nanoparticle drug delivery is addressing these issues, and has made several 
promising advancements for efficient delivery of both chemotherapeutic drugs 
and gene therapy.  
1.4 Nanoparticles and their applications in drug and gene delivery. 
1.4.1 Introduction to nanomedicine. 
Medical nanotechnology, or nanomedicine, is rapidly gaining interest in the 
field of oncology. The National Cancer Institute (NCI) Alliance for 
Nanotechnology in Cancer is currently supporting nine multi-disciplinary research 
and development centers, twelve nanotechnology platform partnerships, and six 
training centers nationwide. The NCI’s Nanotechnology Plan includes six areas 
of interest, including the design of multifunctional therapeutics towards 
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addressing critical issues in drug delivery such as improving drug solubility and 
stability, prolonging drug half-lives in plasma, minimizing off target effects, and 
concentrating drugs at the target site36. Nanotechnology is traditionally defined as 
sub-micron sized molecular devices or nanoparticles predominantly ranging from 
5 nm to 500 nm in at least one dimension. There continues to be significant 
efforts in designing methods to incorporate therapeutic agents into biocompatible 
nanodevices including polymer nanoparticles, liposomes, micellar systems, 
inorganic nanoparticles, nanotubes, and dendrimers. Table 2 lists a few 
examples of nanoparticle therapeutics that are currently approved by the FDA or 
in clinical trials. For reference, Figure 1 compares various nanoparticles to 
common biological structures including hemoglobin, which is approximately 5 nm 
is size, to the human pupil, which ranges from 4-9 mm. Nanovectors for drug 
delivery typically contain a core material or matrix, a therapeutic payload, and 
surface modifications. Of interest are polymer nanoparticles, which have been 









Table 2: Examples of nanoparticle therapeutics37-39. 
NANOCARRIER NAME FORMULATION INDICATION STATUS 
INORGANIC 
NANOPARTICLE 
Ferumoxide Iron oxide MRI 
contrast agent 
Liver imaging Approved 
1996 
 CYT-6091 TNFα-PEG-gold Solid tumors Phase I 






































Zevalin Anti-CD20 conjugated 






PEG – polyethylene glycol, PLA – Polylactic acid, PLGA - poly(lactic-co-glycolic) acid, TNF – 
tumor necrosis factor, tSVPTM – targeted Synthetic Vaccine Particle. 
 
 




1.4.2 Drug encapsulated polymer nanoparticle pharmacokinetics. 
Langer et al40 first described a method for incorporating proteins and 
macromolecules into polymers in 1976. The field of polymer drug delivery has 
continued to evolve and generate an array of novel applications41,42. Many 
polymers are safe to use clinically, and the most extensively studied is 
poly(lactic-co-glycolic acid) (PLGA), which was approved by the FDA in 1969. 
PLGA nanoparticles are being formulated to target specific tumors and deliver a 
host of agents including chemotherapeutics or RNAi43-45. Upon exposure to 
physiologic solutions, PLGA undergoes hydrolysis into biocompatible 
metabolites, glycolic acid (GA) and lactic acid (LA), which are eventually 
metabolized through the citric acid cycle(Figure 2). Biodegradable, polymer 
nanoparticles provide several distinct advantages as a drug delivery vector 
including tunable payload release characteristics and superior pharmacokinetics.  
 
Figure 2: Hydrolysis of poly(lactic-co-glycolic) acid. 
These properties are most apparent when delivering lipophilic or rapidly 
degradable agents. The majority of clinically available chemotherapeutic agents 
are lipophilic. A common measurement of lipophilicity is the distribution 
coefficient, log(D), where D is the ratio of solute concentration in octanol to the 
solute concentration in aqueous buffer in both ionized and non-ionized forms. 
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Log(D) values larger than zero indicate greater solute partitioning into the 
hydrophobic solvent relative to water46. Figure 3 illustrates the spectrum of 
distribution coefficients at physiologic conditions for currently approved anti-
neoplastic agents, and Table 3 lists the specific values for individual agents. The 
PLGA matrix releases encapsulated drugs at a sustained rate, allowing for both 
solubilization of drugs within the intravascular space, and zero order release 
kinetics. When compared to repeat free drug boluses, zero order release kinetics 
are more amenable for delivering drug concentrations within the therapeutic 
window. Free drug boluses result in pulsatile plasma concentrations. Levels 
above the minimal tolerated concentration may result in serious toxicity, and 
levels below the minimum effective concentration will be sub-therapeutic(Figure 
4). The ratio of LA to GA subunits can be adjusted to tune the rate of drug 
release, allowing for release profiles ranging from days to months47. PLGA 
nanoparticles can be scaled for industrial manufacturing and stored for extended 
periods48. Encapsulating unstable small molecules or readily degradable proteins 
and oligonucleotides in core polymeric matrix will protect them from physiologic 
factors that would normally facilitate its clearance. Certain compounds are readily 
inactivated via hepatic metabolism or circulating proteases and endonucleases. 
Additionally, the glomerular filtration unit in the kidneys rapidly clears compounds 
smaller than 10 nm. Although nanoparticles avoid renal clearance, they tend to 
accumulate in the mononuclear phagocyte system (MPS). Surface conjugation 
with polyethylene glycol (PEG) improves particle circulation by reducing uptake 
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into the MPS49. In turn, delivery via nanoparticles will extend drug half-life, 
allowing for better control of circulating drug concentrations.  
 
Figure 3: Distribution coefficient of common anti-neoplastic agents. 
Table 3: Lipophilicity of common anti-neoplastic agents. 
CLASS SUBCLASS DRUG LOG(D) 
ALKYLATING Aziridines Mytomycin -0.49 
 Ethylenimine Thiotepa 0.52 
 Methylhydrazine Procarbazine 0.08 
 Methylmelamine Altretamine 2.32 
 Nitrogen Mustards Busulfan -0.52 
  Chlorambucil 0.55 
  Cyclophosphamide 0.23 
  Ifosfamide 0.23 
  Mechlorethamine 0.87 
  Melphalan -0.71 
 Nitrosureas Carmustine 1.3 
  Lomustine 2.76 
 Platinum Carboplatin -1.09 
  Cisplatin -3.58 
  Oxaliplatin 0.52 
 Tetrazines Dacarbazine -0.29 
  Temozolomide -1.32 
ANTIMETABOLITES Anti-folates Methotrexate -4.9 
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  Pralatrexate -4.35 
  Pemetrexed -4.76 
 Purine analogues Azathioprine 0.63 
  Cladribine 0.02 
  Fludarabine -0.4 
  Mercaptopurine -0.63 
  Thioguanine -1.12 
 Pyrimidine analogues Azacitidine -1.99 
  Capecitabine -0.67 
  Cytarabine -1.94 
  Decitabine -1.93 
  Gemcitabine -0.47 
  Floxuridine -0.4 
  Fluorouracil -5.59 
ANTI-MICROTUBULES Epothilones  Ixabepilone 1.77 
 Taxanes Docetaxel 6.55 
  Paclitaxel 7.38 
 Vinca alkaloids Vinblastine 3.69 
  Vincristine 2.27 
  Vinorelbine 4.86 
CYTOTOXIC ANTIBIOTICS Anthracyclines Bleomycin -2.13 
  Dactinomycin -4.04 
  Daunorubicin 1.23 
  Doxorubicin 1.12 
  Epirubicin 1.12 
  Idarubicin 1.47 
 Cephalotaxine Omacetaxine 2.66 
HORMONE THERAPY Aromatase inhibitors Aminoglutethimide 1.41 
  Anastrozole 0.97 
  Exemestane 3.11 
  Letrozole 1.91 
  Testolactone 2.52 
 Selective estrogen 
receptor modulators 
Tamoxifen 6.58 
  Toremifene 6.51 
 Anti-androgen Bicalutamide 4.94 
  Enzalutamide 2.13 
TARGETED THERAPY G protein receptor 
inhibitors 
Vismodegib  2.98 
 Histone Deacetylase 
inhibitors 
Vorinostat 0.86 
 mTOR inhibitor Everolimus 3.35 
  Temsirolimus 2.96 
 Proteasome inhibitor Bortezomib 2.45 
  Carfilzomib 6.71 
17 
 
 Retinoids Alitretinoin 4.19 
  Bexarotene 5.63 




 Tyrosine kinase 
inhibitors 
Axitinib 4.15 
  Bosutinib 4.93 
  Cabozantinib 4.82 
  Dasatinib 1.84 
  Erlotinib 2.38 
  Gefitinib  3.97 
  Imatinib 2.08 
  Lapatinib 5.1 
  Nilotinib 5.14 
  Pazopanib 1.96 
  Ponatinib 3.39 
  Regorafenib 5.26 
  Sorafenib 5.16 
  Sunitinib 1.33 






  Irinotecan 2.71 
  Topotecan 0.45 
 Topoisomerase II 
inhibitors 
Etoposide 0.30 




Figure 4: Nanoparticle pharmacokinetics. 
1.4.3 Passive and active targeting. 
Nanoparticle systems also have unique properties that allow for both 
passive and active targeting of tumors. Due to up regulation of proangiogenic 
signaling, most solid tumors are hypervascular. However, the new vessels have 
abnormal architecture and are highly permeable. The tumor mass also has poor 
lymphatic drainage, allowing for accumulation of macromolecules greater than 
approximately 40 kDa within its microenvironment. Nanoparticles utilize this 
phenomenon, or the enhanced permeability and retention (EPR) effect, to target 
solid tumors. The ideal size range to benefit from the EPR effect is between 10 
nm to 200 nm. Particles that are too small will be renally cleared, preventing 
accumulation into the tumor site, and particles that are too large will not 
adequately penetrate the tumor vasculature and interstitial space50,51.  
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Particle surface modifications can be incorporated to improve cell targeting 
and internalization while bypassing certain forms of multidrug resistance52. 
Nanoparticles coupled with surface ligands or antibodies can localize to tissue 
expressing the associated receptors or antigens. Certain ligand receptor 
interactions will facilitate receptor-mediated endocytosis, which can further 
enhance payload delivery. Surface ligand or antibody coupling can achieve 
densities high enough to interact efficiently with target sites, and these 
techniques lend themselves well to cancer therapies. Multiple tumors up regulate 
growth factor receptors, like ErbB2 in certain breast cancers, which can be 
targeted with anti-ErbB2 surface antibodies53. Various cancer lines up regulate 
surface antigens, including fetoprotein, human carcinoembryonic antigen, and 
human chorionic gonadotropin antigen, which provides multiple targets for 
antibody mediated targeting37. Additionally, there are a wide array of cell 
penetrating peptides (CPPs) or targeting peptides that can facilitate interactions 
with tumor cells or tumor endothelium. Established conjugation chemistries 
provide facile mechanisms for surface modifying polymer nanoparticles with 
targeting peptides. Zhou et al54 optimized multiple CPPs for improved particle 
endocytosis, and Teesalu et al55,56 used the novel internalizing RGD (iRGD) 
peptide to target nanoparticles to the tumor endothelium. The RGD peptide 
sequence recognizes the αvβ3/αvβ5 integrins up regulated on tumor endothelial 
cells. The iRGD peptide is a cyclic tumor homing structure which contains both 
the RGD sequence and a CendK/R element. The iRGD structure is readily 
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cleaved by proteases, allowing for exposure of the CendK/R element and 
subsequent tissue penetration through binding of neuropilin-1(Figure 5)57.  
 
Figure 5: Mechanism for iRGD binding and penetration. 
In addition to ligand coupled targeting, nanoparticles can be delivered 
locally via intravenous catheters, inhalation, transdermal patches, or intravitreal 
administration52. Local delivery of chemotherapeutic agents can minimize several 
of the harmful side effects associated with common cancer therapies. New 
polymer delivery vehicles allow for targeted and combination cancer therapies, 
which can ultimately decrease the development of drug resistance while 
simultaneously minimizing the side effect profile. 
1.4.4 Nanoparticle gene therapy. 
Gene therapy is the cellular delivery of nucleic acids in order to modulate 
gene expression towards treating disease. After introduction, the therapeutic 
DNA either integrates into the host genome or persists as an episomal vector. 
Phenotypic modulation is achieved either through gene addition, gene correction, 
or gene knockdown58. Gene addition is generally the most common approach, 
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and alters cell behavior by introducing genetic material and consequent proteins 
that are inherently missing in the host. Gene correction is less common, and 
utilizes DNA recombination technology, like zinc finger nucleases, triplex forming 
oligonucleotides, or CRISPR-Cas technology, to alter or correct genomic 
sequences59-62. Finally, gene knockdown through RNAi has received significant 
enthusiasm. Due to the complex nature of cancer pathogenesis and multitude of 
signaling pathways involved in disease progression, isolating druggable 
molecular targets can become increasingly difficult. Often, tumor cells have 
altered transcription factor activity, which are difficult to target through small 
molecule drugs. Therefore, gene therapy can provide an alternative strategy for 
designing effective and specific therapies against cancer.  
The FDA approved its first clinical trial in gene therapy in 1990. Michael 
Blease conducted an ex vivo gene therapy trial on two children with adenosine 
deaminase deficiency, a form of severe combined immunodeficiency (SCID), with 
limited efficacy63. Subsequent trials in treating SCID through ex vivo gene 
delivery, however, have demonstrated better long term results64,65. In 1998, A 
team in Scandinavia demonstrated the first successful gene transfer from in vivo 
gene delivery into the brain66. Currently, there have been greater than 1,800 
approved clinical trials worldwide67. More than 60 percent of current trials are 
designed to treat cancer, and viral vectors continue to be the most popular 
approach68. China was the first country to approve a commercial gene 
therapeutic, which is currently being used to treat head and neck cancer69, and 
there are multiple therapies nearing the final stages of clinical testing 
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worldwide70. Of interest, the CTL019 trial, at the University of Pennsylvania, has 
shown promising results using chimeric antigen receptor therapy for treating B-
cell neoplasms71-73. The patient’s T-cells are modified ex vivo using a lentiviral 
vector to express chimeric surface antibodies against CD19, which is expressed 
on B-cells. Twelve of 14 pediatric patients with acute lymphoblastic leukemia 
have responded to therapy, and eight experienced complete remission. Twelve 
of 24 adult patients with chronic lymphocytic leukemia have responded to 
therapy, and five of those responders have attained complete remission74.  
There has been significant progress in the field, despite earlier setbacks, 
including the death of 18 year old Jesse Gelsinger in 199975, and the 
development of T cell leukemia in multiple patients receiving gene therapies for 
SCID76,77. Severe side effects like mortality and carcinogenesis were intimately 
related to the viral delivery vector. The dangers of viral gene therapy are due to 
the associated acute immune response, immunogenicity, and oncogenesis. Even 
the recently successful CTL019 therapy, has significant toxicities including the 
development of cytokine release syndrome which can progress into macrophage 
activation syndrome71. Safety concerns are the underlying basis for research into 
synthetic vectors for gene delivery. Further, viruses have limited payload capacity 
and are difficult for large-scale production. Non-viral vectors are advantageous 
due to their safety profile, low cost, large scale manufacturing potential, stability, 
and capacity for a larger nucleic acid payload78,79. The main limitation of non-viral 
vectors is their lower transfection efficiency. Table 4 lists the array of different 
vectors for gene therapy, and their associated transfection efficiency and toxicity. 
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PLGA nanoparticles can deliver nucleic acids with minimal cytotoxicity, but they 
have relatively low transfection efficiency. Incorporation of counter ions, like 
spermidine, and surface functionalization with cell targeting or cell penetrating 
peptides have improved DNA loading and particle transfection54,80. However, 
their transfection efficiency remains far less than the polycationic nanoparticle 















Table 4: Methods of gene delivery56,58,78,79,81,82. 





INORGANIC Calcium Phosphate II I/II 
 Gold   
 Magnetic   
 Silica   
 Quantum dots   
CATIONIC LIPIDS Emulsions II/III II/III 
 Liposomes   
 Lipid nanoparticles   
CATIONIC POLYMERS PAMAM II/III II/III 
 PbAE   
 PEI   
 Terpolymers   
CATIONIC PEPTIDE GALA,KALA II/III II/III 
 Poly-L-lysine   




POLYMER Chitosan II I/II 
 Copolymer micelles   
 PLGA, PLA   








PHYSICAL Needle II/III II/III 
 Ballistic DNA 
injection 
  
 Electroporation   
 Sonoporation   
 Photoporation   
 Magnetofection   
 Hydroporation   
VIRAL Retroviral III III 
 Adenoviral   
 Adeno-associated   
I-low, II-medium, III-high, GALA- glutamic acid-alanine-leucine-alanine, KALA- lysine-alanine-
leucine-alanine, PAMAM-polyamidoamine, PbAE- poly(beta-amino ester), PEI-Polyethyleneimine, 
PLA-polylactic acid, PLGA- poly(lactic-co-glycolic acid).  
 
Cationic liposomes are currently the gold standard for nanoparticle 
transfection. The first gene therapy trial using cationic liposomes occurred in 
1992, and approximately 13 percent of all gene therapy trials worldwide are using 
liposomal nanoparticles. Toxicity, however, can also be a major concern of 
liposomes. Additionally, liposomes are heterogeneous and relatively unstable, 
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causing significant obstacles for large-scale pharmaceutical production83. 
Liposomes are readily inactivated in the serum, which can lower the high 
transfection levels commonly seen in vitro84. Serum instability, clearance, and 
cytotoxicity are common obstacles facing many non-viral gene delivery vectors. 
Polycationic polymers, like polyethyleneimine (PEI), have high in vitro 
transfection potential but can also be considerably cytotoxic. PEI induces 
channel formation on the mitochondrial membrane and subsequent caspase 
activation and apoptosis85. Other polycations, like poly-L-lysine (PLL) and 
chitosan, are less toxic but provide lower transfection. Further, PLL can stimulate 
an immune response due to the introduction of foreign amino acid sequences, 
and chitosan, at high doses can result in hypolipidemia in vivo83.  
In addition to cytotoxicity, multiple barriers can obstruct effective particle 
transfection(Figure 7)58,81,82. Gene loaded particles need to protect their payload 
from nucleolytic enzymes while in circulation, and ultimately penetrate into the 
target tissue at adequate concentrations. Polymers like PLGA can encapsulate 
nucleic acids, protecting them from endonucleases. Similarly, condensing the 
negative phosphate bonds of nucleic acid chains with cationic polymers into 
polyplexes can also protect the oligonucleotides from degradation during 
circulation. As discussed earlier, nanocarriers can utilize the EPR effect or 
specific integrin binding in order to target the tumor endothelium and promote 
vessel extravasation. By conjugating peptides, like iRGD, particles can 
preferentially accumulate in specific tumor locations.  
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After bypassing the vascular endothelium, the particle will then need to 
traverse the interstitial space towards the target cell. Nanoparticle uptake 
depends on a variety of biophysiochemical characteristics of both the particle and 
cell surface. The cell surface is highly heterogeneous, both spatially and 
temporally, due to a variety of membrane structures, molecular interactions, and 
transport processes. Therefore, uptake will depend on both chance interaction 
and specific particle cell surface dynamics86. Surface charge and particle size are 
intimately associated with uptake efficiency. The numerous cell surface proteins 
provide an overall negative charge on the plasma membrane, which readily 
interacts with the positive charge on certain nanocarriers. Optimal particle 
diameter ranges from 50-120 nm, and smaller particles experience faster 
uptake87. Additional studies report clathrin or caveolin mediated endocytosis  are 
capable of internalizing particles with diameters upwards to 500 nm, yet 
internalization efficiency decreases with increased size88. Due to particle charge 
and size, uptake via membrane channels or transmembrane diffusion is unlikely. 
Therefore, energy dependent endocytosis is a primary route for cellular entry and 
can occur through multiple mechanisms. Figure 6 illustrates the five major 
endocytic pathways. Each route has its associated molecular players, 
compartment size, and intracellular fate89-91. There are multiple destinations for 
the early endosome, and the majority will render the genetic material ineffective. 
Figure 7 depicts different destinations for the endosomal cargo, and early escape 
is necessary for subsequent gene activity. Endosomal acidification and payload 
degradation through the lysosomal pathway (L) is a common barrier for 
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transfection. Sequestration within vesicles (V) can also occur, as can 
externalization through trancytosis or endosomal recycling, all of which will 
render the genetic payload ineffective.  
 
Figure 6: Pathways for endocytosis. 
AP – antennapedia, CDC42 - cell division cycle 42, CLIC-D - dynamin-dependent clathrin-
independent carriers, CLIC-DI - dynamin- and clathrin-independent carriers, ER – endoplasmic 
reticulum, RGD - arginine-glycine-aspartic acid, TAT – transactivator of transcription, TGN – 





Figure 7: Barriers to gene therapy. 
CTL – cytotoxic T lymphocyte, L – lysosome, V – vesicle. R – endosomal recycling, T – 
transcytosis. 
Additionally, ligand surface modifications not only assist particle targeting, 
but may also facilitate uptake. CPPs are classes of short 30-35 amino acid 
peptides, rich in arginine and lysine, that promote cargo uptake via multiple 
mechanisms. The prototypic CPP are the HIV transactivator of transcription 
(TAT) peptide and antennapedia (AP) peptide isolated from Drosophila 
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antennae92. Currently, there are multiple studies evaluating these peptides, and 
their influence on cargo endocytosis. The specific mechanism for endocytosis 
varies, and several studies have suggested multiple routes of entry for individual 
CPPs93-95. Of interest, Zhou et al. evaluated histidine modifications of several 
CPPs, and found that flanking AP with five histidine residues (mAP) significantly 
increased nanoparticle transfection efficiencies54. Additionally, particle surface 
modifications with anti-receptor antibodies, or surface conjugation with folate and 
transferrin can increase cargo uptake96-98. Figure 6 summarizes targeting 
strategies for specific endocytic pathways. Strategies to improve endosomal 
escape include utilizing fusogenic peptides or the proton sponge effect. Certain 
viral peptides are known to promote endosomal disruption in a pH dependent 
manner, and similar peptides have been synthesized to improve gene 
transfection when incorporated with DNA polyplexes99. Due to immunotoxicity of 
viral proteins, synthetic peptides have been designed to enhance endosomal 
disruption as well. These polymers are converted from hydrophilic to hydrophobic 
structures upon protonation in the endosome, which consequently allows for 
vesicle membrane lysis100. Cationic polyplexes, like PEI or polyamidoamine 
(PAMAM) dendrimers, can also promote endosomal escape through the proton 
sponge mechanism101. During endosomal acidification, the protons pumped into 
the lumen via the vacuolar-ATPase are buffered by the polyamine dendrimers. 
The impairment in acidification results in increase proton influx, which passively 
recruits chloride ions in order to maintain charge balance. The greater 
accumulation of osmotic agents results in endosomal swelling and consequent 
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lysis. Additionally, co-delivery of chloroquine analogues has been shown to 
improve gene transfection through unclear mechanisms. There is support that 
chloroquine can potentially act as pH buffering agents as well, displace cationic 
complexes from nucleic acids, or alter biophysical properties of the released 
genetic material102.  
If the nanocarrier does escape the endosome, depending on the genetic 
payload, the next challenge will be nuclear targeting. Plasmid delivery will require 
translocation into the nucleus to attain transcription, whereas siRNA or miRNA 
activity resides in the cytoplasm. Additionally, cytosolic nucleases will eventually 
degrade cytosolic DNA or RNA. Polyplexes can potentially protect against 
cytosolic nucleases and travel along microtubules towards the nucleus via 
nonspecific charge interactions. Additionally, random redistribution during mitosis 
can result in gene uptake within the nucleus. Nuclear localization signals (NLS), 
which are naturally occurring cationic peptides, are used to deliver proteins to the 
nucleus. Polyplexes may act similarly to these NLS due to their inherent positive 
charge. NLS can also be conjugated to plasmids to imporove nuclear targeting 
and transfection103. Co-delivery of trans-cyclohexane-1,2-diol (TCHD) has been 
shown to improve gene transfection through non-selective gating of the nuclear 
pore104. Within the nucleus, vector genome persistence may be an issue if the 
exogenous material does not integrate with the hose genome. The episomal 
DNA can persist in quiescent tissue; however, gene expression will become 
increasingly transient in rapidly dividing cells. Repeat dosing may then be 
required to sustain therapeutic transfection levels. Vector integration into the host 
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genome can lead to greater persistence at the risk of gene disruption via 
insertional mutagenesis. Additionally, epigenetic alterations may disrupt gene 
expression regardless of genome integration. Persistence and sustained gene 
expression are vital for diseases requiring permanent gene expression. For 
acquired diseases like cancer, transient transfection may be adequate to achieve 
a therapeutic effect. Alternatively, minicircle DNA vectors lacking bacterial DNA 
has been shown to be expressed at high levels in vivo for extended periods, yet 
obstacles in their mass production limit their utilization105.  
The host immune response is a significant barrier to efficient gene therapy 
as well. Particle components, extranuclear nucleic acids, and transgene products 
can activate an immune response. It is difficult to predict human immune 
responses since most animal models fail to replicate the human immune systems 
accurately. Not only is the immune response hard to extrapolate into humans, but 
transfection efficiencies measured in animals do not always correlate into 
humans58. Generally, the immune response elicited by viral vectors is far more 
severe than that of nanoparticles, as most particles are only as immunotoxic as 
their cargo. Although, foreign DNA payloads can also illicit an interferon response 
which can potentially lead to immunotoxicity or decreased transfection 
efficiencies106. The inflammatory response may be due to the presence of 
unmethylated CpG dinucleotides present on plasmid DNA. Mutating the 
immunostimulatory CpG motifs or co-delivering immunosuppressants can 
decrease the inflammatory response and elevate transgene expression107. 
Additionally, higher surface charges present on liposomes have induced 
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secretion of cytokines including tumor necrosis factor (TNF), interleukin 12, 
nuclear factor κβ (NFκβ), and interferon γ. However, these immunostimulatory 
effects may be beneficial in cancer therapies108-110.  
The MPS plays a major role in nanoparticle clearance. Nanoparticles 
readily adsorb plasma proteins upon introduction to systemic circulation, and are 
consequently opsonized and phagocytized by the MPS. Due to hepatic and 
splenic filtration, particles tend to accumulate in those organs111. Smaller 
particles and a neutral surface charge result in lower levels of opsonization and 
phagocytosis. Surface modifications can reduce protein adsorption and 
entrapment within the MPS. For instance, PEG not only decreases protein 
adsorption and phagocytis into the MPS as discussed earlier, but it can also 
decrease platelet or erythrocyte interactions112. Unfortunately, the shielding 
effects of particle PEGylation is transient and can hinder target particle cell 
interactions as well. Poloxamer and poloxamine have also been used to reduce 
recognition from immune cells, decrease uptake within the MPS, and prolong 
circulation time113. Additionally, surface functionalization with self-peptides, like 
CD47, can delay macrophage mediated clearance114. Nanoparticle design 
becomes critical in order to address the multiple barriers involved in gene 






Table 5: Strategies for addressing gene delivery barriers via nanoparticles. 
BARRIER STRATEGY 
1. STABILITY IN TRANSPORT AND TARGETING. Local delivery 
Polymer encapsulation 
Polyplexes 
Surface modifications (see text) 
2. UPTAKE. Fabricate at optimal particle size 
Surface modifications (Figure 6 and 
text) 
3. ENDOSOMAL ESCAPE. Chloroquine analogues  
pH sensitive fusogenic or synthetic 
peptides 
‘Proton sponge’ polymers 
4. TRANSPORT INTO NUCLEUS. Nuclear pore gating with TCHD  
Nuclear targeting via NLS 
5. PERSISTENCE AND TRANSCRIPTIONAL 
ACTIVITY. 
Insertional vectors 
Minicircle DNA vectors 
Repeat dosing 
6. IMMUNE RESPONSE. Co-deliver immunosupressants  
Fabricate at optimal particle size 
Minicircle DNA vectors 
Mutate CpG motifs on plasmid DNA 
Neutral surface charge 
Surface modifications (see text) 
NLS – Nuclear localization signal, TCHD - trans-cyclohexane-1,2-diol. 
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1.5 Apoptosis and cancer. 
1.5.1 Apoptotic signaling and evading cell death. 
Apoptosis is a highly regulated mode of cell death, where internal 
signaling cascades promote degradation of nuclear DNA and cellular proteins. 
During the process, the plasma membrane remains intact, and eventually 
neighboring cells or macrophages engulf the cellular remnant. Activation of 
cysteine proteases, or caspases, is a primary driver of apoptosis. Two upstream 
circuits, divided into the extrinsic and intrinsic pathways, regulate this signaling 
cascade. The extrinsic pathway is initiated by extracellular death inducing signals 
that bind to death receptors (DRs) on the cell surface. The majority of these 
receptors are members of the TNF receptor family, and they bind to specific 
ligands including the Fas ligand (FasL), TNFα receptor, and tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL). DR binding activates caspase-
8, which subsequently activates caspase-3 and -7, resulting in the execution of 
apoptosis. Caspase-8 can directly regulate the mitochondrial pathway as well by 
activating proapoptotic proteins, Bax and Bak, which form channels in the outer 
mitochondrial membrane, and in turn releases cytochrome c. In the cytoplasm, 
cytochrome c engages downstream caspases towards inducing apoptosis. Anti-
apoptotic proteins maintain cell viability by binding and inhibiting Bax and Bak 
and caspase activation. Cell survival mediators and growth receptor signaling 
provide anti-apoptotic signals through the Bcl-2 family or inhibitor of apoptosis 
proteins (IAPs). Cellular stresses including loss of growth factors, oxidation, 
endoplasmic reticulum stress due to misfolded proteins, and DNA damage can 
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inhibit anti-apoptotic proteins and activate pro-apoptotic Bcl family proteins. This 
subclass of Bcl proteins is commonly known as BH3-only proteins, and they 
activate Bax and Bak towards releasing cytochrome c. BH3-only proteins can 
directly inhibit Bcl-2 as well. Crosstalk between the extrinsic and intrinsic 
pathways tightly regulates the caspase mediated apoptotic pathway(Figure 8)115.  
Chemotherapies and radiotherapies can induce apoptosis in susceptible 
cancer cells. Many antineoplastic agents increase DR expression via a TP53 
mechanism or DR ligand synthesis116,117. However, tumor cells have developed 
numerous mechanisms to reduce or even avoid apoptosis. The most prominent 
is the loss of tumor suppressor TP53, which senses DNA damage and promotes 
apoptosis through directly activating caspase-8, Bax, and Bak. Loss of TP53 will 
desensitize cells to ionizing radiation or DNA damaging chemotherapeutics. 
Additionally, tumors can modulate any part of the circuitry, through either up-
regulating growth receptor signaling or Bcl-2 expression, down-regulating BH3-
only or IAP protein expression, or inactivating extrinsic DR signaling7. 
Augmentation of the intrinsic and extrinsic apoptotic pathways is intimately 
associated with cancer development, and in turn linked to the development of 
drug resistance118. Apoptotic signaling is a promising target for anticancer 
therapies, since there are multiple signaling networks to target, and direct 




Figure 8: Apoptosis signaling cascade. 
CPT – camptothecin.  
1.6 Combination therapies and synergism. 
1.6.1 Nanoparticle combination therapies. 
Combination therapies with nanoparticles are promising due to their 
manufacturing benefits, and ideal pharmacokinetics and biophysiochemical 
characteristics119. Combination drug analyses have often been difficult to 
translate from in vitro to in vivo experiments. Delivering multiple agents in vivo is 
complicated due to their independent pharmokinetics, biodistribution, and 
clearance. Nanoparticle delivery systems will consolidate these properties into 
one vehicle and ultimately ensure that the targeted tumor cells receive both 
agents at a ratiometric dose. Therefore, the optimal drug ratio can be tuned in 
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vitro, and subsequently translated to the clinic effectively. Combining multiple 
agents into one carrier can also streamline manufacturing and infusion 
processes, overcome batch to batch variability, and lower costs. The patient will 
also receive smaller doses of the nanocarriers, which can potentially lower 
toxicity associated with the delivery vector. There have been several reports of 
co-delivering multiple anti-cancer agents using nanocarriers, and some are 
reaching clinical trials120-124. Only a few, however, are capable of co-delivering 
both small molecule chemotherapeutics and genetic material. As these carriers 
show considerable promise, improvements are still necessary in improving 
transfection potential, while maintaining ideal particle size, surface charge, 
loading, targeting, and biocompatibility. Additionally, evaluation of synergistic 
interactions is rare, especially when using nanoparticle vectors for co-delivery. 
Several of the reported nanocarriers were only able to show improved anti-
cancer effects at high doses.  
1.6.2 Chou-Talalay analysis of synergism.  
Designing therapies with synergistic agents will allow for reduced drug 
dosing and toxicity. Two agents act synergistically when their combined effect is 
greater than the sum of their individual effects. Analysis of synergism is complex 
and there are numerous methods for determining true synergism. Several of 
these methods contradict the other. Although commonly presented, the 
arithmetic sum of individual effects does not necessarily provide a cutoff for 
synergism, since you cannot have effect levels greater than one. Potency as well 
as efficacy is important in determining synergy, and therefore a dose response 
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curve is necessary for accurate analysis. Chou and Talalay derived the 
combination index (CI) and median effect equation (MEE) in 1984, and have 
since established a precedent for analyzing synergism125,126. The MEE is derived 
from the mass action law, and describes the behavior of many biological 
systems. In fact, the Michaelis-Menten, Hill, Henderson-Hasselbalch, and 
Scathcard equations can be derived from the MEE. Therefore, the mechanisms 
of action and conventional kinetic constants for the individual agents are not 
necessary to evaluate synergism via this method. The linearized MEE uses the 
dose response data to determine Dm, the median effective dose, and m, the Hill-
type coefficient(Equation 2). The coefficient for the linear regression is an 
indicator for the applicability of the Chou-Talalay analysis. At each effect level, 
the corresponding doses, Dalone,1, Dalone,2, Dcomb,1, and Dcomb,2, can be tabulated to 
determine a CI value, using Equation 3, which can consequently be evaluated 
according to Table 6. The doses for individual agents during the combined dose 
response analysis are determined using the known ratio between the two 
components. Finally, a calculated dose-reduction index (DRI) can provide the 
fold change in drug dosing required to achieve a similar effect(Equation 4). A 
computer program, CompuSyn, is available to assist with the Chou-Talalay 
analysis127. Chaowanachan et al. evaluated drug synergism between tenofovir 
and nanoparticle antiretrovirals using the Chou-Talalay analysis, however, to my 
knowledge, there have not been any previous analyses of synergism for 













D – dose, Dm – median effect dose, fa – fraction affected, fu – fraction unaffected, m – Hill-type 
coefficient. 
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CI – combination index, Dalone,1 – dose of drug 1, Dalone,2 – dose of drug 2, Dcomb,1 – combination 
dose of drug 1, Dcomb,2 – combination dose of drug 2. For mutually exclusive drugs, ∝ = 0, and for 










Table 6: Evaluation of Combination Index values125,126. 
CI RANGE EVALUATION 
<0.10 Very strong synergism 
0.10-0.30 Strong synergism 
0.30-0.70 Synergism 
0.70-0.85 Moderate synergism 
0.85-0.90 Slight synergism 
0.90-1.10 Nearly additive 
1.10-1.20 Slight antagonism 
1.20-1.45 Moderate antagonism 
1.45-3.30 Antagonism 
3.30-10.0 Strong antagonism 
>10.0 Very strong antagonism 
 
Equation 4: Dose-Reduction Index 
𝐷𝐷𝐷𝐷𝐶𝐶1 = 𝐷𝐷𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑎𝑎,1/𝐷𝐷𝑐𝑐𝑐𝑐𝑚𝑚𝑐𝑐,1 
DRI – Dose-reduction index, Dalone,1 – dose of drug 1, Dcomb,1 – combination dose of drug 1. 
1.7 Candidate agents. 
Apoptosis is often deregulated in cancer cells. As most FDA approved 
modes of cancer therapy result in modulation in apoptosis, alterations in cell 
death signaling is common in many tumor subtypes and will ultimately result in 
resistance to most treatment protocols. New strategies to improve cancer 
therapies can focus on improving apoptosis through combination therapies 
targeting both the extrinsic and intrinsic pathways. Rational nanomedicine design 
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for combination cancer therapies should utilize the attractive biophysicochemical 
properties of nanoparticles, for providing multi-modal cancer therapies. 
1.7.1 Camptothecin. 
Numerous small molecule chemotherapeutic agents are promising 
candidates for delivery via polymer nanoparticles. Camptothecin (CPT) is a 
hydrophobic, topoisomerase I (topo-1) inhibitor, and lends itself well to polymer 
nanoparticle delivery. It is an alkaloid extract from the Chinese tree, 
Camptotheca acuminate, and was first identified in 1966 through a natural 
product screen for antitumor agents. Due to its hydrophobic nature, CPT readily 
penetrates eukaryotic cell membranes and targets topo-1 within minutes. CPT 
stabilizes topo-1 after binding to DNA, and prevents religation129. As the 
replication fork collides with the cleaved strand, it induces a double stranded 
break resulting in cell cycle arrest and apoptosis. Downstream signaling after 
DNA breaks has also been shown to increase expression of NFκβ and surface 
DRs130. Mutations in DNA repair pathways can further sensitize tumor cells to 
CPT, however, deficiencies in the cell cycle checkpoint process can have the 
opposite effect. CPT has a low affinity to topo-1, which necessitates prolonged 
infusions. Initial clinical trials evaluating CPT were halted due to severe toxicities 
including myelosuppression and hemorrhagic cystitis. The major limiting factors 
were the associated toxicity, stability, and low solubility in water. CPT contains a 
lactone component that is required for binding topo-1. However, the lactone is 
readily hydrolyzed in aqueous solutions to the inactive carboxylate form and 
readily binds serum albumin(Figure 9). Decreasing pH can promote reformation 
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of the active form of CPT, which may provide a targeting benefit given that tumor 
microenvironments are relatively acidic131. Water-soluble analogues, such as 
topotecan and irinotecan, are currently FDA approved and are used as both first 
line and refractory therapies130. PLGA particles can readily encapsulate CPT due 
to its hydrophobic qualities, provide protection from lactone hydrolysis and 
albumin binding while in circulation132. The molecule also has a strong 
fluorescence (370 nm excitation, 428 nm emission) which can allow for facile 
loading and release measurements133. CPT is a promising candidate drug for 
combination therapies via polymer nanoparticles due to its chemical properties 
and unique mechanism of action. 
 
 
Figure 9: Reversible hydrolysis of camptothecin. 
1.7.2 TNF-related apoptosis inducing ligand (TRAIL)  
Scientists at Genentech and Immunex identified the new TNF-superfamily 
member peptide, TRAIL, through analyzing the human genome database for 
homologous sequences to TNF134. TRAIL is a strong inducer of apoptosis via the 
extrinsic pathway, and it preferentially targets cancer cells independently of TP53 
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status135. Through binding DRs, specifically DR4 and TP53 regulated DR5, 
TRAIL activates the caspase mediated apoptosis cascade(Figure 8). Its 
physiologic role is not completely delineated, yet it has been implicated in 
antitumor surveillance. Natural killer cells (NK cells), monocytes, and T cells all 
express TRAIL to induce apoptosis in cancer cells. T cells can both display 
TRAIL and secrete soluble forms of the ligand136. Recombinant soluble TRAIL 
induces apoptosis in a variety of solid and liquid tumors, with minimal associated 
systemic toxicities137-144. Normal tissues exhibit a tightly regulated mechanism to 
control against TRAIL induced cell death involving decoy receptors. Certain 
recombinant forms of TRAIL can promote apoptosis in hepatocytes, astrocytes, 
and keratinocytes, which may be related to high order multimerization of DRs 
secondary to peptide aggregation. Alternatively, soluble, zinc-bound, non-
aggregating, recombinant TRAIL induces less off target apoptosis, however, it is 
less effective in killing tumor cells136,145. Therapeutically, alternate DR targeting 
using TNAα has resulted in septic shock responses due to activation of NFκβ, 
and FasL resulted in hepatic failure136. TRAIL is a safer alternative since it rarely 
targets normal cells, and it minimally activates NFκβ signaling. Several cancer 
cell lines highly express DR4 and DR5, and multiple lines up-regulate DR 
expression upon exposure cytotoxic agents and ionizing radiation135-137. TRAIL’s 
safety profile, and tumor specific, TP53 independent, activity are promising 
qualities. The biggest hurdle for the clinical use of recombinant TRAIL peptide is 
its serum instability and rapid clearance. Even the larger, multimeric formulations 
are rapidly cleared by the kidneys. In vivo studies in mice report TRAIL activity 
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for only 3-5 minutes, and current therapies in animal models require prolonged 
infusions at high doses shortly after tumor implantation145,146.  
Despite TRAIL’s broad range of anti-tumor activity, newer studies are 
isolating several resistant cell lines, which may also benefit from combination 
therapies. Multiple chemotherapeutic agents, including doxorubicin and CPT, act 
synergistically with recombinant TRAIL therapy resulting in significant tumor 
regression or complete remission. Of interest, TRAIL gene transfection has been 
shown to kill resistant prostate cancer cell lines without the need for 
doxorubicin147. A phase I trial using an adenoviral vector for TRAIL transfection 
has been completed for treating prostate cancer148. TRAIL transgene expression 
has been implicated with cell death as well as bystander cell toxicity in tumors, 
suggesting that 100 percent cell transfection is not necessary for therapeutic 
efficacy149. Targeted cellular transfection can potentially allow for sustained 
TRAIL expression with minimal interference from systemic clearance. 
Transfection may provide an alternative strategy for TRAIL therapies that would 
overcome the need for long, high dose, recombinant protein infusions.  
1.7.3 Combination therapies with camptothecin and TNF-related apoptosis 
inducing ligand. 
CPT analogues and TRAIL produce significantly enhanced apoptotic activity 
when administered in combination150. For instance, irinotecan (CPT-11), was 
shown to cooperate with TRAIL to produce TP53 independent apoptosis of colon 
cancer cells. Hepatic metastases from both TP53 proficient and deficient tumor 
cells were eliminated with combined TRAIL and CPT-11 therapy. Ravi et al. 
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suggest that a TP53 independent mechanism may assist in the cross-talk 
between the two apoptosis inducing agents151. Several tumor cell lines have 
demonstrated favorable responses to combined TRAIL and CPT analogue 
therapies, including colon cancer, prostate cancer, brain cancer, breast cancer, 
and lung cancer152-155. Timing of agent delivery was an important factor in 
therapy, as the majority of these studies found that pretreatment with 
chemotherapeutic drugs or radiation enhanced subsequent recombinant TRAIL 
activity. In turn, nanoparticle delivery systems may provide an ideal system for 
providing combination CPT and TRAIL gene therapies.  
2 Statement of Purpose and Hypothesis  
Our understanding of tumor biology has improved significantly, yet cancer 
remains a highly prevalent and lethal disease. Small molecules, 
immunotherapies, and gene therapies are providing numerous therapeutic 
options and the potential for personalized medicine. However, there are still 
significant obstacles in treating cancer, primarily due to the development of tumor 
resistance and severe side effects. Combination therapies are becoming 
increasingly common as front line therapies, yet side effects often limit treatment 
dosing, duration, and ultimately efficacy. Targeted therapies, utilizing multiple 
synergistic agents tailored for individual patients, can potentially address these 
obstacles. Polymer nanoparticle technology provides an attractive vector for 
delivering multi-modal therapies against cancer in a targeted manner. We 
hypothesize that by utilizing multi-layered polymer nanoparticles (MLNPs), 
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we can rationally design a multi-functional delivery vector for combination 
gene and small molecule therapy towards synergistically inhibiting tumor 
growth. There have been previous studies examining the use of nanoparticles 
for multi-modal therapies. However, improvement in gene transfection is 
necessary, while maintaining ideal particle biophysicochemical properties. 
Combination therapies via nanovectors will also require thorough analysis of 
synergism in order to reduce therapeutic dosage. Therefore, our investigations 
will address the following: 
1. Improve PLGA particle transfection in vitro by adjusting particle 
fabrication parameters, utilizing surfaces modifications, and co-
encapsulating transfection enhancing small molecules.  
2. Examine tumor death kinetics in vitro in response to TRAIL gene 
transfection and CPT exposure towards optimal delivery with MLNPs.  
3. Demonstrate synergistic decrease in tumor cell growth in vitro by co-
delivering CPT and a plasmid encoding for the TRAIL gene (pTRAIL).  
4. Demonstrate efficacy in reducing tumor growth in vivo by co-delivering 
CPT and pTRAIL gene via MLNPs.  
3 Methods   
All of the authors were involved in developing the final design for the MLNPs. 
The first author performed all of the experiments detailed in this thesis. All of the 
authors were involved in the analysis and interpretation of the data.  
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3.1 Materials and cell culture. 
All reagents were purchased from Sigma Aldrich unless otherwise noted. 
Plasmid DNA (pDNA) expressing luciferase (pGL4.13; pLuc), green fluorescent 
protein (GFP; pEGFP; pGFP), and TRAIL (pEGFP-TRAIL; pTRAIL) were 
purchased from Promega and Addgene respectively. Human embryonic kidney 
293 (293T), human glioblastoma (U87), human colorectal adenocarcinoma 
(HCT116), and human breast adenocarcinoma (MDAMB231) cell lines were 
obtained from ATCC (American Type Culture Collection). All cells were grown in 
same culture media (CM), which consisted of DMEM medium (Life Technologies) 
supplemented with 10% fetal bovine serum (Life Technologies), 100 units/ml 
penicillin, and 100 mg/ml streptomycin (Life Technologies), in a 37C incubator 
containing 5% CO2. Fluorescence was determined using a UV-Vis 
spectrophotometer (Cary 50 Bio UV-Vis Spectrophotometer, Varian, Palo Alto, 
CA). 
3.2 Nanoparticle fabrication. 
Nanoparticles (NPs) were fabricated using established emulsion 
evaporation techniques. PLGA (50:50 PLGA Carboxylic Acid End Group; i.v. 
~0.67 dL/g; Absorbable Polymers: Pelham, AL) was dissolved in organic solvent 
(ethyl acetate (EA) or dichloromethane (DCM)) at a ratio of 50 mg polymer to 1 
mL organic solvent to form the oil phase (O). For drug loaded particles, CPT was 
dissolved at designated concentrations (5 mg/mL to 0.0001 mg/mL) in O. The 
polymer solution was then added dropwise to the outer aqueous phase (W2) 
which consisted of deionized water containing 2.5% (v/v) poly-vinyl alcohol (PVA) 
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at a ratio of 1 mL O to 2 mL W2. The O/W2 emulsion was sonicated on ice three 
times for 10 s (Tekmar, 600 Watts 38%). When indicated, TCHD was 
incorporated by adding 12.5 uL of 200 mg/mL TCHD in deionized water as the 
inner aqueous phase (W1), and added dropwise to O. This W1/O emulsion was 
sonicated as above, and then added to W2 at the same ratio as above. The final 
O/W2 or W1/O/W2 emulsion was then diluted 25 fold into 0.3% (v/v) PVA in 
water. The diluted emulsion was left stirring at 400 rpm for at least 3 h. NPs were 
then centrifuged at 13,000 rpm for 15 min at 4C. All centrifugation steps were 
performed using these parameters. The supernatant was then decanted and the 
pellet was resuspended in 4 mL water by sonication for 10 sec in a water bath 
sonicator. Particles were always resuspended using these sonication 
parameters. Resuspended NPs were flash frozen in liquid nitrogen and 
lyophilized for long-term storage at -20C.  
3.3 Surface modification 
MLNPs were fabricated by forming PLGA nanoparticles as above with an 
outer aqueous phase containing PEI (3.3 mg/mL). After spinning overnight, the 
particles were centrifuged and resuspended in 1 mL of pH 4.0 sodium acetate 
buffer containing 25 µg/mL of pDNA. The particle suspension was loaded on a 
rotisserie shaker for 15 min at room temperature (RT), and then centrifuged and 
resuspended in 1 mL of 10 mg/mL PEI in pH 4.0 sodium acetate buffer. The 
particle suspension was loaded on a rotisserie shaker for 15 min at RT, and then 
centrifuged and resuspended in 1 mL of pH 7.4 phosphate buffered saline (PBS) 
containing 1 mg/mL of a heterobifunctional PEG linker (Peirce Thermo Scientific). 
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The PEG linker was functionalized with N-hydroxysuccinimide (NHS) and 
maleimide (MAL). The particle suspension was loaded on a rotisserie shaker for 
30 min at RT, and then centrifuged and resuspended in 1 mL of pH 7.4 PBS 
containing 2 mg/mL mAP (W. M. Keck Facility at Yale University). The particle 
suspension was loaded on a rotisserie shaker for 30 min at RT, and then 
centrifuged and resuspended in 4 mL water. Final MLNP suspension was flash 
frozen in liquid nitrogen and lyophilized for long term storage at -20C. Step by 




Figure 10: Surface modification of MLNPs. 
3.4 Cellular Transfection 
For 96 well plates, the culture volume was 100 µL and for 48 well plates, 
the culture volume was 250 µL. Cells were seeded at designated seeding 
densities in CM without antibiotics, and transfected 24 h later. For polymer NP 
transfections, the CM was removed and replaced with NPs or MLNPs 
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resuspended in CM containing antibiotics at designated particle concentrations. 
The particles were resuspended via brief sonication. For lipofectamine 
transfections, 6.4 µL of Lipofectamine 2000 (Life Technologies) reagent was 
resuspended in 100 µL of OptiMEM (Life Technologies) at RT for 5 min. The 
lipofectamine solution was then added to an equivalent volume of pDNA in 
Optimem at a desired concentration for 20 min at RT. The lipid nanoparticle 
solution was then added to each cell culture well at 10% of the working volume. 
The CM containing lipid particles was aspirated and replaced with CM containing 
antibiotics as stated above after 5 h.  
3.5 Cytotoxicity. 
Human embryonic kidney 293 cells (ATCC; 293T) were seeded at 
approximately 30,000 cells/cm2, and, 24 h later, transfected with 1mg/mL of 
particles and lipofectamine containing an equivalent pDNA dose as described 
previously. Cell viability was determined 48 h post transfection by adding Celltiter 
Blue reagent to each well at 10% of the culture volume. After 2 h, 90 µL of the 
culture medium was transferred to a 96 well UV transparent plate (Corning) and 
assayed for fluorescence at 560 nm excitation and 590 nm emission. The 
fluorescent signal for each treatment group was normalized to the no treatment 




3.6 Particle evaluation.  
3.6.1 Nanoparticle characterization. 
Scanning electron microscopy (SEM) was used to determine particle size 
and morphology. Dried nanoparticles were applied onto double-sided carbon 
tape and sputter coated with gold, under vacuum, for 30 s with a 40 mA current 
(Dynavac Mini Coater, Dynavac, USA). An XL-30 ESEM-FEG (FEI Company) 
having an acceleration voltage of 10 kV was used to visualize the nanoparticles. 
The average particle size was determined using available image analysis 
software (Image J, National Institute of Health). Particle hydrodynamic diameter 
and surface charge was determined by dynamic light scattering on a Zetasizer 
Nano ZS (Malvern Instruments, Ltd.). 
3.7 CPT loading and in vitro release. 
Polymer particles were dissolved at 1-10 mg/mL in dimethyl sulfoxide 
(DMSO) for 1 h at RT. Afterwards, the dissolved particle solution was diluted 10 
fold in CPT extraction buffer (EB; PBS containing 1% sodium dodecyl sulfate and 
1% 1 N HCl v/v) for 1 h at RT. CPT was dissolved in DMSO at 5mg/mL and 
diluted in CPT EB containing 10% DMSO (v/v) for the standard curve. Particle 
and CPT samples in EB were added to a 96 well UV transparent plate and 
evaluated for CPT fluorescence at 370 nm excitation and 428 nm emission. 
Blank NP or MLNP fluorescence was subtracted from the drug sample signal and 
evaluated for loading against the standard curve.  
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To determine the CPT release characteristics, particles were suspended 
in 1 mL of PBS at 3-6 mg/mL, placed in a 10 kDa snake skin dialysis tubing, and 
sutured closed. The tubing was then placed into 15 mL conical tubes containing 
10 mL PBS, which were loaded onto rotisserie shakers at 37C for 96 h. At 
designated time points, 1 mL of the supernatant was aliquoted for subsequent 
analysis and the remaining buffer was decanted. Ten mL of fresh PBS was 
added to each tube after each collection. Thirty µL of EB containing 3.33% 
DMSO (v/v) was added to 970 µL of sample. CPT was dissolved in DMSO at 5 
mg/mL and diluted with EB containing 1% DMSO (v/v) for the standard curve. 
Samples and standards were analyzed for CPT content as described above.  
3.7.1 Plasmid loading and in vitro release. 
MLNPs were dissolved at 2 mg/mL in DMSO for 1 h. The particle solution 
was diluted 10 fold in Tris-EDTA (TE) buffer containing 12.5 mg/mL heparin 
sulfate overnight at RT. Stock λ DNA was diluted in 12.5 mg/mL heparin sulfate 
in TE buffer for the standard curve. Particle samples and standards were 
transferred to a 96 well UV transparent plate, and combined with an equal 
volume of Quant-iT PicoGreen reagent (Life Technologies) diluted in TE buffer 
for 5 min at RT. Samples were assayed for fluorescence at 480 nm excitation 
and 520 nm emission. Blank MLNP fluorescence was subtracted from the 
plasmid sample signal and evaluated for loading against the standard curve. 
Plasmid release characteristics were determined by resuspending 0.5 
mg/mL particles in a 15 mL conical tube containing 10 mL of PBS. The tubes 
were placed on a rotisserie shaker at 37C. At each time point, 1 mL of 
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supernatant was aliquoted and replaced with 1 mL of fresh PBS. Each sample 
was diluted 10 fold in TE buffer containing 12.5 mg/mL heparin sulfate overnight 
at RT. Released plasmid content was measured using the Quant-iT PicoGreen 
reagent as previously described.  
3.7.2 PEI Loading and in vitro release. 
MLNPs were dissolved at 2 mg/mL in 0.1 M sodium hydroxide (NaOH) 
overnight at RT. PEI was dissolved in 0.1 M NaOH at 1 mg/mL and diluted for the 
standard curve. Samples and standards were transferred to a 96 well UV 
transparent plate, and 10 µL of 7 mg/mL fluorescamine in acetone was added to 
each well (v/v 10:1) for 10 min at RT, and then assay for fluorescence at 390 nm 
excitation and 475 nm emission. Blank MLNP fluorescence was subtracted from 
the PEI sample signal and evaluated for loading against the standard curve. 
PEI release characteristics were determined by resuspending 0.5 mg/mL 
particles in a 15 mL conical tube containing 10 mL of PBS. The tubes were 
placed on a rotisserie shaker at 37C. At each time point, 1 mL of supernatant 
was aliquoted and replaced with 1 mL of fresh PBS. Each sample was diluted 10 
fold in 0.1 M NaOH overnight at RT. PEI content was measured using the 
fluorescamine reagent as previously described.  
3.8 Functional evaluation. 
3.8.1 Transfection analysis. 
For the population transfection studies, MLNPs were loaded with pLuc (BL 
MLNP), and 293T cells were transfected with 1 mg/mL MLNPs and an equivalent 
plasmid dose using lipofectamine. Expression of luciferase was quantified using 
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Luciferase Assay Reagent (LAR; Promega) 42 h post transfection. The CM was 
aspirated, and cells were lysed using lysis buffer. After one freeze thaw cycle, the 
lysates were spun down at 15,000 rpm for 3 min, 20 uL of supernatant was 
added to 100 uL of LAR, and luminescence was measured using a Glomax 
luminometer (Promega) over a 10 s integration period. Sample luminescence 
was normalized to total sample protein, which was determined using a 
bicinchoninic acid (BCA) protein assay (Thermo Scientific).  
Percent cellular transfection was determined by loading MLNPs and lipid 
NPs with pGFP towards transfecting 293T cells as above. Cells were imaged at 
48-72 h post transfection using a Leica SP5 confocal microscope. Flow 
cytometry analysis was performed by resuspending the 293T cells in PBS, 
centrifuging once at 2,000 rpm for 3 min, and resuspending the pelleted cells in 
Fluorescence-activated cell sorting (FACS) buffer. The resuspended cells were 
then analyzed with a BD Biosciences FACScan to determine percent 
transfection.  
3.8.2 in vitro cytotoxicity. 
The effect of CPT exposure and pTRAIL transfection timing on death 
kinetics was determined in vitro using free CPT and pTRAIL delivered with 
lipofectamine. Cells (U87, HCT116, and MDAMB231) were seeded in 96 well 
culture plates (Corning) at 2,500 cells/cm2. All treatment groups were transfected 
with pTRAIL 48 h after seeding, and exposed to CPT 24 h before (-24 h), during 
(0 h), or 24 h after (+24 h) CPT exposure. Treatment controls included NT, and 
CPT exposure alone at the respective time points. Treatment groups were 
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analyzed for viability 48 h post transfection via Quant-iT Celltiter Blue reagent as 
described earlier. Figure 11 illustrates the experimental design for the death 
kinetics experiments.  
 
Figure 11: Experimental design for evaluating camptothecin and TRAIL 
plasmid transfection death kinetics. 
 
 MLNPs were then fabricated to deliver both CPT and pTRAIL as 
described earlier (CT MLNPs). The initial loading of CPT in O1 ranged between 
0.1 to 0.0001 mg/mL (CT1-3 or CL1-3, Table 8). U87, HCT116, and MDAMB231 
cells were seeded in 96 well culture plates at 5,000 cells/cm2, and were 
transfected with particles 24 h later. The doses of particles ranged from 3 mg/mL 
to approximately 0.004 mg/mL, and cell viability was determined 72 h post 
transfection using the Quant-iT Celltiter reagent as described earlier. CT2 
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MLNPs, CL2 MLNPs, BT MLNPs, and CPT NPs were evaluated for efficacy in 
reducing tumor growth in vitro.  
3.8.3 Evaluating synergism. 
The dose effect data comparing the fraction of tumor cells affected (Fa) to 
drug or plasmid doses were analyzed using the Chou-Talalay analysis in order to 
evaluate for synergism. Particle doses were converted to ug/mL of CPT or 
pTRAIL according to particle loading characteristics. The data were analyzed 
using the Compusyn software in order to determine Dm, CI, and DRI values as 
detailed earlier (Equation 2-4).  
3.8.4 Antitumor evaluation of MLNPs in vivo.  
CT2 MLNPs, BT MLNPs, CL2 MLNPs, and BL MLNPs were fabricated as 
described earlier, however, both mAP (1 mg/mL) and iRGD (0.25 mg/mL; 
Thermo Scientific) were used in the final conjugation step. Male athymic  nude 
(NCr-nu/nu) mice were purchased from Taconic and maintained in a sterile 
environment. All procedures were approved by the Institutional Animal Care and 
Utilization Committee of Yale University. Tumors were established by injecting 
mice with 2e106 HCT116 tumor cells subcutaneously. Experiments were started 
when tumor volumes reached approximately 30-50 mm3. Mice were randomly 
divided into groups of three to six mice per treatment group as follows: group 1, 
PBS control; group 2, CT2 MLNP; group 3, CL2 MLNP; group 4, BT MLNP; 
group 5, BL MLNP. Each mouse was injected with 1.5 mg of particles via tail vein 
three days a week until the end of the experiments. Each injection consisted of 
100 µL of 1 mg/mL particles in PBS. Tumor size was measured using traceable 
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digital vernier calipers (Fisher). The tumor length (l) and the width (w) 
measurements were obtained in order to calculate tumor volume (V =1/2*lw2). 
The growth curve was plotted with respect to tumor volumes. The animals were 
killed two days after tumors grew over 1 cm3, excised, and formalin-fixed for 
immunohistochemistry. Slides of serial sections were stained with TUNEL for 
analysis of therapeutic effects. 
3.9 Statistical analysis. 
For all in vitro studies, test groups were conducted in replicates of three, and 
compared using a two-sample heteroscedastic t-test. One-way ANOVA analysis 
was performed to determine the statistical significance of treatment-related 
changes for the in vivo studies. A p value smaller than 0.05 was considered to be 
significant for all analyses. All error bars denote the standard error for each 
group.  
4 Results  
4.1 Nanoparticle fabrication. 
4.1.1 Surface modifications and biotoxicity. 
Changes in particle morphology and size were analyzed during each step 
of the MLNP fabrication protocol. Figure 12 displays SEM images of the MLNPs 
at different fabrication stages. Sequential surface modification of PLGA particles 
with PEI and pDNA did not alter particle size or morphology as all particles were 
spherical with average dry diameters between 113-123 nm. Table 7 lists the 
measurements for both the dry and hydrodynamic particle diameters in addition 
59 
 
to surface charge, PEI loading, and plasmid loading. The initial surface 
complexation of PLGA particles with PEI (PLGA-P) did increase particle surface 
charge from -23.3 mV to 32.3 mV with a total load of 3.7 ug of PEI per mg of 
particle(Figure 13). There was a relative decrease in surface charge and a 
minimal drop in PEI content with subsequent surface condensation of pDNA 
(PLGA-PD). The second layer of PEI increased the total content to 44.5 ug of 
PEI per mg particle with a concomitant increase in surface charge to 26.6 mV 
(PLGA-PDP). Conjugation of mAP to the outer PEI layer via an heterobifunctional 
PEG cross-linker did not alter surface charge dramatically, however, there was a 
relative drop in total PEI content with each conjugation step(Figure 13). Cell 
proliferation was measured using the Celltiter Blue assay, and viability was 
determined by normalizing the signal to groups receiving NT. Toxicity was 
calculated by subtracting viability from one. Initial surface modification with PEI 
(PLGA-PD) rendered particles significantly toxic to cells (Figure 14). Only after 




Figure 12: The effect of surface modification on particle size. 




Figure 13: The effect of surface modifications on particle surface charge 
and polyethyleneimine (PEI) loading. 
P – PEI, D – pDNA 
 
Figure 14: The effect of surface modifications on particle toxicity. 
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4.2 Particle evaluation.  
4.2.1 Loading and release studies. 
PEI and plasmid loading of the MLNPs after each fabrication step is listed 
in Table 7. The particles analyzed in Table 7 were all prepared with EA as the 
organic phase. There is a decrease in plasmid content with each fabrication step, 
and the final MLNP plasmid load was approximately 575 ng per mg of particle. 
CPT encapsulation within MLNPs was tunable relative to initial CPT loading 
(Table 8). Decreasing the initial CPT load from 0.1 mg CPT per mg PLGA (CT1 
MLNP) to 0.001 mg CPT per mg PLGA (CT2 MLNP) resulted in an approximately 
10 fold decrease in loading to approximately 0.018-0.071 µg/mg, with minimal 
change in loading efficiency. Decreasing the initial CPT load even further to 
0.0001 mg CPT per mg PLGA (CT3 MLNP) resulted in a decrease in loading to 
approximately 0.006-0.010 µg/mg while maintaining a similar loading efficiency. 
Using DCM as the organic phase resulted in similar CPT loading trends. There 
was batch to batch variability in loading which is detailed in Table 8. Surface 
modification did not alter CPT release profiles(Figure 15A). CPT release and PEI 
dissociation from CT2 MLNPs prepared with EA occurred readily, achieving 80-
90% release within 24 hours (Figure 15B). Plasmid release lagged behind CPT 





















PLGA 122.7 +/- 
24.7 
 -23.3 +/- 2.27 -- -- 
PLGA-P   32.3 +/- 1.01 3.7 +/- 0.6 -- 
PLGA-PD 113.6 +/- 
26.6 
193.1 +/- 2.7 20.6 +/- 1.9 3.3 +/- 1.5 2.70 +/- .009 
PLGA-PDP 122.8 +/- 
24.7 











206.1 28.2 +/- 2.0 24.2 +/- 0.1 0.575 +/- .045 
 
Table 8: Camptothecin encapsulation. 
 CPT LOADING (MG CPT/ 
MG POLYMER) 
MLNP CPT ENCAPSULATION 
(MG CPT/MG PLGA) 
LOADING 
EFFICIENCY (%) 
CT1 0.1 2.900e-3 2.9 
CT2 0.001 0.018e-3 to 0.071e-3 10 




Figure 15: Particle release profiles. 
4.3 Functional evaluation. 
4.3.1 Cellular transfection. 
Luciferase activity in 293T cells was measured 48 hours post transfection 
with MLNPs and lipofectamine. Surface modification with PEI and pLuc (PLGA-
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PD, PLGA-PDP) allowed for transfection of 293T cells(Figure 16A). Further 
modification with 5kDa PEG and mAP (PLGA-PDP-PEG-mAP) resulted in 
greater luciferase activity after transfection. However, in these initial formulations, 
lipofectamine still provided greater transfection than the MLNPs. Transfection 
was subsequently improved by utilizing a lower molecular weight PEG (1kDa) 
and co-encapsulating TCHD (Figure 16B). Preparing particles with EA instead of 
DCM in the organic phase improved MLNP transfection levels resulting in 
luciferase activities after transfection that was comparable to lipofectamine. The 
optimal MLNPs were those fabricated using EA, 1kDa PEG, and TCHD. 
Subsequent transfection of 293T cells at lower seeding densities with these 
MLNPs resulted in significantly greater luciferase activity than 
lipofectamine(Figure 16C). To identify the fraction of cells that were successfully 
transfected, the percent cell transfection was determined by measuring GFP 
expression via confocal microscopy and flow cytometry. Figure 17 displays 
fluorescent images of 293T cells taken 48 hours (Figure 17A,C) and 72 hours 
(Figure 17B,D) post transfection with MLNPs and lipofectamine carrying pGFP. 
The fluorescent signal for the MLNP groups increased from 48-72 h, however, 
the signal from the lipofectamine groups decreased over this period. Transfected 
cells were analyzed using flow cytometry at 72 hours post transfection to 
determine percent cellular transfection. MLNP percent cellular transfection was 
measured at 37% compared to 58% obtained by lipofectamine (Figure 18). A 
clear shift in the FL1 peak could be observed for the MLNP group but was not 
apparent in the lipofectamine group. Total cell number was greater for the MLNP 
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groups than the lipofectamine groups at both 48 and 72 hours post transfection, 
and can be visualized on the confocal images(Figure 17).  
 








Figure 18: Percent cell transfection. 
4.3.2 in vitro cytotoxicity. 
Before evaluating MLNPs for combination in vitro drug and gene delivery, 
cell death studies were conducted on U87, HCT116, and MDAMB231 cell lines to 
determine optimal timing of CPT exposure and pTRAIL transfection(Figure 19). 
Exposure to CPT concurrently with pTRAIL transfection resulted in the greatest 
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relative decrease in viability for all cell lines. Transfection with seven ng/well of 
pTRAIL resulted in significant decreases in cell viability with concomitant therapy. 
HCT116 cells demonstrated the largest relative decrease in cell viability with CPT 
and pTRAIL gene therapy(Figure 19B). MLNPs loaded with both CPT and 
pTRAIL (CT MLNP) were tested for efficacy in reducing tumor cell proliferation in 
vitro(Figure 20). CT MLNPs were fabricated with increasing pTRAIL to CPT 
loading ratios. All particles contained approximately 575 ng of pTRAIL per mg of 
PLGA, and were loaded with decreasing CPT content as detailed in Table 8. 
After exposing cells to an effective 0.01 µM dose of CPT via MLNPs, CT 2 
MLNPs resulted in the greatest effect on reducing HCT116 tumor growth in 
vitro(Figure 20). The CT2 MLNP formulation was then used for subsequent 




Figure 19: Tumor death kinetics relative to camptothecin exposure and TNF 




Figure 20: The effect of multi-layered nanoparticle loading and cell death. 
 
Table 9: Camptothecin to TNF related apoptosis inducing ligand ratio. 
 CPT:pTRAIL RATIO 
pTRAIL dose (ng/well) 25 nM CPT 2.5 nM CPT 
7.000 0.128 0.036 
3.500 0.257 0.071 
1.750 0.514 0.142 
0.875 1.029 0.285 
 
Table 10: Camptothecin to TNF related apoptosis inducing ligand ratio for 
multi-layered nanoparticle formulations. 







4.3.3 Evaluating synergism. 
Delivering CPT and pTRAIL via MLNPs shifted the dose effect curves to 
the left for all cell lines(Figure 21). Figure 21A and B compare the dose effect 
curves of CT2 MLNPs to CPT MLNPs containing the pLuc plasmid (CL2 MLNPs) 
and CPT NPs respectively on all cell lines. Figure 21C illustrates the dose effect 
curves comparing CT2 MLNPs and blank MLNPs loaded with pTRAIL (BT 
MLNPs). Chou-Talalay analysis of CT2 MLNPs compared to CL MLNPs and BT 
MLNPs as well as CPT NPs and BT MLNPs were performed, and the CI and DRI 
for both CPT and pTRAIL can be seen in Figure 22 and Figure 23 for all Fa 
levels. Table 12 and Table 13 provide the CI and DRI values at a Fa of 50% in 
addition to the Dm for each agent. The linear regression coefficients for fitting the 
dose effect data to the MEE transformation (Equation 2) were above 0.90 for all 
dose affect curves(Table 11). CompuSyn analysis on all cell lines produced CI 









Figure 22: Chou-Talalay synergism analysis of CT2 MLNPs compared to 




Figure 23: Chou-Talalay synergism analysis of CT2 MLNPs compared to 
CPT NPs and BT MLNPs. 
 
Table 11: Goodness of fit of the Chou-Talalay analysis. 
DOSE AFFECT CURVE CHOU-TALALAY LINEAR REGRESSION COEFFICIENT 
 U87 HCT116 MDAMB231 
CL2 MLNP 0.98 0.92 0.97 
CPT NP 0.94 0.97 0.94 
CT2 MLNP 0.98 0.99 0.99 
BT MLNP 0.94 0.94 0.99 
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Table 12: Combination index, dose-reduction index, and median effect dose 
for CT2 MLNPs and CL2 MLNPs. 
 CT2 MLNP CPT Dm (nM) 
CELL LINE CI CPT DRI  pTRAIL DRI  CT2 MLNP CL2 MLNP 
U87 0.53 3.14 4.66 19.7 43.4 
HCT116 0.45 3.51 6.09 7.15 17.6 
MDAMB231 0.33 7.38 5.01 19.4 263 
 
Table 13: Combination index, dose-reduction index, and median effect dose 
for CT2 MLNPs and CPT NPs. 
 CT2 MLNP CPT Dm (nM) 
CELL LINE CI CPT DRI  pTRAIL DRI  CT2 MLNP CPT NP 
U87 0.39 5.80 4.66 19.7 107 
HCT116 0.35 5.43 6.09 7.15 33.7 
MDAMB231 0.33 7.38 5.01 19.4 281 
 
4.3.4 Antitumor evaluation of MLNPs in vivo.  
The initial results of the in vivo therapeutic study are presented in Figure 
24. Average tumor volumes are shown in figure, and there is a decrease in tumor 
growth for both the BT MLNPs and CT2 MLNPs treatment groups. This 




Figure 24: in vivo antitumor effects of MLNPs. 
5 Discussion  
5.1 Nanoparticle fabrication and characterization. 
Multifunctional PLGA nanoparticles were synthesized for the simultaneous 
delivery of CPT and pDNA. CPT was loaded into the core of PLGA nanoparticles, 
which were subsequently surface modified to facilitate electrostatic complexation 
with pDNA. Surface modifications of PLGA nanoparticles were implemented by 
utilizing established conjugation chemistries. Figure 10 illustrates the step by 
step surface modifications involved in fabricating the MLNPs. The PLGA polymer 
used for making the particle core is carboxy terminated, and the pKa values of 
the acid groups on PLGA are 3.86 and 3.83156. Therefore, the multiple positively 
charged amines on the PEI dendrimers will complex with the negative carboxyl 
end groups(Figure 10C-D) during precipitation in W2. Although, there may PEI 
within the particle, creating a PLGA-PEI blend, the majority of the polymer PEI 
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will likely be on the surface due to hydrophilic interactions. The surface PEI 
coating contains multiple primary, secondary, and tertiary amines with pKa 
values ranging from 4.5, 6.7, and 11.6 respectively157. PEI is well known for its 
ability to form electrostatic complexes with pDNA. In this case, the condensation 
of plasmid DNA and the second PEI layer was conducted at pH 4 to ensure 
protonation of all of the amine groups(Figure 10E-H), so that the greater positive 
charge of PEI can facilitate electrostatic coupling between the protonated amines 
and negative phosphate backbone of DNA. Heterobifunctional PEG molecules 
were then conjugated to the amine groups on PEI (Figure 10I-J). The PEG cross-
linker contained terminal NHS and maleimide groups. NHS is a highly stable 
leaving group which facilitates amide bond formation with the amines on PEI 
through a SN2 reaction. Subsequently, the maleimide end group readily reacts to 
thiol groups, like those found on cysteine terminated mAP, forming thioether 
bonds (Figure 10J-L). Each surface modification step was performed with a 
molar excess of conjugating reagents.  
The modular design of the MLNP provides the capacity for alternative 
functionalization given the requirements for the delivery system. The mAP ligand 
could be replaced with other CPPs or targeting ligands in order to increase 
localization and uptake at the desired tissue site. These MLNPs utilized 
maleimide thiol conjugation chemistry to attach mAP to the outer surface. 
However, other conjugation protocols can be utilized to attach CPPs, ligands, or 
antibodies. PEG cross-linkers can be terminated with a variety of functional 
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groups other than NHS and maleimide, allowing for potential conjugation with a 
variety of compounds.   
Functionalizing core PLGA particles with multiple layers of PEI allowed for 
loading of pDNA in addition to encapsulating our candidate small molecule, CPT. 
Particle diameter remained constant at approximately 115 nm after surface 
modifications (Table 7), which is beneficial for passive targeting since the ideal 
particle size for utilizing the EPR effect is between 10 to 200 nm. Surface 
attachment of PEI was successful, as indicated by a change in surface charge 
from -23.3 mV to 32.3 mV, and a PEI load of 3.7 ug/mg of particle (Figure 13). 
The ability to condense DNA onto the particle is due to electrostatic condensation 
onto the positively charged PEI coating. As expected, the condensation of 
negatively charged DNA decreased the surface potential. Subsequent addition of 
another layer of PEI increased the surface potential again to values ranging from 
26.6 to 31.1 mV. The bulk of the total particle PEI content appears to be located 
in the second layer as the total weight normalized PEI load increased 
substantially, from 3.7 ug/mg to 44.5 ug/mg, with the addition of the second layer.  
There was a measurable decrease in PEI content with each subsequent 
conjugation, which is likely due to partial dissociation of the outer PEI layer with 
each conjugation and centrifugation steps. A similar effect was observed on total 
plasmid content, as the initial weight normalized plasmid load of 2.7 ug/mg 
decreased to approximately 575 ng/mg after the final modification step. The 
sequential conjugation of PEG and mAP to the MLNP surface was performed at 
pH 7.4. At a neutral pH, the primary and secondary amines on PEI are 
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deprotonated, which destabilizes the electrostatic coupling with DNA. After 
centrifugation, the resulting pellet was sonicated in order for re-dispersion of 
particles into solution. The sonication energy may also cause shedding of PEI 
and pDNA from the particle. Although electrostatic coupling does allow for facile 
plasmid loading, there is a measurable inefficiency resulting from partial PEI and 
DNA loss with each conjugation step. As a result, the final plasmid dose is 
approximately 21% of the initial plasmid load.  
Surface coating with PEI did render the particles highly toxic to 293T cells, 
which may be due to the interactions of surface PEI with the cellular 
membrane(Figure 14). Coating with PEG-mAP likely hindered these cytotoxic 
interactions, which significantly decreased toxicity to levels much lower than 
lipofectamine.  
PLGA particles readily encapsulate CPT due to the hydrophobic nature of 
the molecule. Previous studies analyzing CPT encapsulation into PLGA 
nanoparticles demonstrated high loading efficiencies133. Similarly, MLNPs were 
able to encapsulate CPT at high loading efficiencies (data not shown); however, 
co-encapsulation with TCHD did decrease CPT loading efficiencies. Double 
emulsion protocols are inherently less efficient for drug loading, which was 
required for co-encapsulating TCHD since it is a hydrophilic molecule. However, 
our goal was ultimately to deliver less CPT, and therefore decreased loading 
efficiencies were not a significant disadvantage for this particular application. In 
fact, delivering a greater ratio of pTRAIL to CPT was preferred. Particle loading 
was therefore decreased by reducing the initial CPT dissolved in the organic 
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phase of the emulsion procedure. Table 8 demonstrates that decreasing the 
initial CPT load per mg of PLGA resulted in reduced final MLNP loading.  
CPT was readily released from MLNPs as approximately 80% was released 
within twelve hours. Surface modifications did not alter the drug release profile 
(Figure 15). The outer PEI layer readily dissociated from the particle as well, with 
80% of the total PEI content being released within twelve hours. There was a lag 
in plasmid release since it required 48 hours for 80% of the total plasmid load to 
be released from the MLNPs. This may suggest that the majority of the plasmid 
is complexed with the first PEI layer. The in vitro release studies were performed 
in buffered saline at physiologic pH. However, the tumor microenvironment and 
the endosomal compartment are acidic, which may influence particle release 
profiles. Additionally, plasmid release analysis was conducted in high levels of 
heparin to promote plasmid dissociation from PEI in order for subsequent 
measurement with the picogreen assay. Plasmid dissociation in vivo will likely be 
more prolonged, which may be beneficial for protecting plasmids from both 
circulating and cytosolic endonucleases.  
5.2 Transfection evaluation.  
The initial goal was to improve MLNP transfection capabilities. Population 
transfection studies were conducted by delivering pLuc to 293T cells via MLNPs. 
As displayed in Figure 16, optimizing particle fabrication parameters resulted in 
high 293T transfection levels that were ultimately comparable to lipofectamine. 
PEI has already demonstrated to be a potent transfection vehicle, but is also 
known to be highly toxic to cells. After coating the outer PEI layer with PEG-mAP, 
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transfection levels measured by luciferase activity increased (Figure 16), which 
was partly a result of the significant decrease in particle toxicity(Figure 14). 
These effects may be due to the inhibition of PEI associated membrane 
disruption and apoptosis with PEG conjugation. The transfection levels, however, 
were still significantly lower than lipofectamine. In addition to coating the PEI and 
minimizing particle toxicity, utilizing a PEG heterobifunctional linker allows for 
subsequent functionalization with a CPP. For the in vitro studies, mAP was used 
to improve cellular transfection since previous studies have demonstrated 
superior transfection capabilities associated with particles functionalized with 
mAP compared to other CPPs54. Surface conjugation with mAP provided similar 
results of significantly improving transfection capabilities.  
The first optimization studies (Figure 16A) used a 5 kDa PEG cross-linker. 
Decreasing the molecular weight of PEG has been shown to increase particle 
transfection, and recent studies suggest 1 kDa PEG molecules were most 
optimal158. MLNPs conjugated with a 1 kDa PEG cross-linker resulted in greater 
transfection levels (Figure 16B). Decreasing PEG size may allow for a greater 
number of PEG units to bind to the PEI coating, which then provides more 
maleimide groups for conjugating mAP. TCHD was also co-encapsulated into the 
PLGA core in order to improve gene transfection. TCHD increases nuclear pore 
patency, which permits plasmid localization into the nucleus. Incorporation of 
TCHD increased transfection levels by a factor of 2-5. Finally, switching the 
organic phase from DCM to EA improved particle transfection. Theoretically, this 
effect is due to the smaller size of the particles. EA diffuses out of the PLGA 
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precipitant upon exposure to the aqueous phase, which favors formation of 
smaller particles due to faster hardening of the particles. MLNPs particles 
fabricated with EA, TCHD, and 1 kDa PEG provided the greatest transfection 
levels, which were comparable to lipofectamine(Figure 16B). The transfection 
results displayed in Figure 16A-B were conducted on cells seeded at 
approximately 50,000 cells/cm2. Figure 16C demonstrates that decreasing the 
seeding density can increase normalized population transfection levels. This may 
be related to the greater amount of particles per cell at lower seeding densities. 
Additionally, the fraction of mitotically active cells may be greater at lower 
densities since higher seeding densities result in confluency earlier. This can in 
turn result in greater particle internalization within the dividing cells. MLNPs are 
more likely to be internalized in mitotically active cells, due to the increased 
probability for random localization within the cytosol or even the nucleus. The 
method of transfection with lipid particles differs, since internalization primarily 
occurs after particle fusion with the plasma membrane. Lipofectamine solutions 
are removed at approximately four hours post transfection due to cellular toxicity, 
which limits their potential for internalization in dividing cells. The greater toxicity 
of lipofectamine may also have a greater effect on cell growth, especially at lower 
seeding densities. The MLNPs remained in the cell culture medium since they 
are non-toxic.  
Percent cell transfection was then determined by transfecting 293T cells 
with pGFP. GFP expression in individual cells can be visualized through confocal 
microscopy and quantified using flow cytometry. Figure 17 provides fluorescent 
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images of GFP expression 48 and 72 hours post transfection with MLNPs (Figure 
17A and B respectively), and with lipofectamine (Figure 17C and D respectively). 
The percentage of cells transfected is higher with lipofectamine, however, there 
was a clear shift in the fluorescence peak for the MLNP group (Figure 18). 
Percent transfection is dependent on total viable cells, which is fewer in the 
lipofectamine groups due to particle toxicity. The fewer viable cells in the 
lipofectamine group may explain why the population transfection levels are 
similar to the MLNP group despite having a greater percent transfection. 
Additionally, the MLNP transfected cells may be expressing higher levels of the 
transgene due to the decreased toxicity of the particle. However, these cells 
should theoretically be producing a greater amount of total protein as well, which 
is incorporated in the normalized values. GFP transgene expression was also 
more stable over time in the MLNP group as GFP signal decreased over time in 
the lipofectamine group. In contrast to the lipid particles, MLNPs gradually 
release their DNA cargo (Figure 15), which will effect long term transgene 
expression levels. This property is typically better for in vivo applications since it 
protects the genetic material from endonucleases for extended periods of time. It 
is likely that a combination of factors is affecting population transfection levels.  
5.3 in vitro cytotoxicity. 
As described earlier (Figure 8), there are multiple mechanisms for cross talk 
between the apoptotic stimulus provided by CPT and TRAIL. The evidence of 
synergism between TRAIL and multiple chemotherapeutics including CPT is 
growing. There are a few clinical trials (NCT00671372, NCT00508625) 
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evaluating the efficacy of recombinant human TRAIL protein and multiple 
chemotherapeutics. Previous nanoparticle research evaluating the delivery of 
either CPT or TRAIL therapy is promising. However, there are no studies 
evaluating the efficacy of combination CPT and TRAIL therapy via a nanovector. 
Further, there has yet to be any evaluation of the effect of CPT and TRAIL gene 
therapy in animals. In many forms of gene therapy for cancer, cell transfection 
efficiency is important since it is theoretically necessary to knockdown gene 
expression in every cancer cell. Even with the most potent transfection vector, 
100% gene transfection is an extremely challenging goal. However, with pTRAIL 
transfection, 100% transfection is not required for therapeutic efficacy. 
Transfected cells can express and secrete TRAIL, and through the bystander 
effect, neighboring, non-transfected cells, are still subjected to apoptosis by 
activation of extrinsic death receptors149. It is unclear if either DR4 or DR5 have 
cytosolic binding sites for TRAIL. The dominant mechanism of cell death, 
whether it occurs internally through TRAIL signaling or externally through TRAIL-
DR interactions, needs further investigation.  
Cancer cell lines have variable sensitivities to CPT and TRAIL. The in vitro 
cytotoxicity screens evaluated the efficacy of combination therapies on U87, 
HCT116, and MDAMB231 cells. Previous studies analyzing the effect of 
combination CPT and the TRAIL peptide suggest that pretreatment with CPT 
sensitizes cancer cells to TRAIL mediated apoptosis. Due to the lag between 
transfection and protein expression, the death kinetics of CPT and pTRAIL 
transfection were studied to determine the optimal timing for each therapy. Figure 
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19 compares the efficacy of reducing tumor growth in vitro with combination CPT 
delivery and pTRAIL transfection via lipofectamine. Subtherapeutic doses of CPT 
and pTRAIL were used in order to appreciate the effect of combination delivery. 
U87 and MDAMB231 cells were exposed to 25 nM CPT (Figure 19A and C). 
Since HCT116 cells are more sensitive, they were exposed to 2.5 nM CPT 
(Figure 19B). Combination therapies were normalized to groups receiving a 
similarly timed CPT dose in order to determine the relative increase in tumor cell 
death. The resulting death kinetics suggest that CPT exposure during or before 
TRAIL transfection provided the greatest reduction in tumor cell growth. The 
most significant effect was seen with CPT delivery during transfection for all cell 
lines. Transgene expression usually occurs 24-48 hours after transfection, which 
coincides with previous timing experiments with combination CPT and TRAIL 
peptide therapies. These results add further support to the theory that CPT 
exposure sensitizes cells to TRAIL, by either up-regulating DR4 and DR5 
expression, or inhibiting Bcl-2 activity(Figure 8)155,159. Furthermore, we can 
deliver CPT and pTRAIL at the optimal timing by using the MLNP delivery system 
(Figure 15B). If other drug and gene formulations were to be evaluated, drug 
release can be tuned by adjusting LA and GA monomer ratio of PLGA if slower 
or faster release was desired. A greater delivery of pTRAIL to CPT resulted in the 
most significant effects (Table 9 and Figure 19). The greater relative increase in 
cell death for the HCT116 groups when compared to the U87 and MDAMB231 
groups is likely due to the smaller CPT to pTRAIL dose.  
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The next goal was to design CT MLNPs that effectively delivered the largest 
ratio of pTRAIL to CPT. In order to evaluate the efficacy of MLNPs in reducing 
tumor growth, pTRAIL was loaded onto CPT encapsulated MLNPs (CT MLNP). 
CPT is a potent anti-cancer agent, and delivering a greater ratio of CPT to 
pTRAIL will provide overwhelming toxicity primarily due to CPT activity. 
Therefore, multiple MLNP formulations with varying CPT to pTRAIL loading ratios 
were fabricated (Table 8). Each formulation was evaluated for its effect on 
inhibiting HCT116 growth in vitro(Figure 20). The CT MLNP groups provided an 
effective 0.01 uM dose of CPT. MLNPs with lower drug loading will therefore 
deliver a greater plasmid dose since more particles were delivered to meet the 
required CPT dose. The optimal formulation was CT2. Since PEI is a base, it 
may contribute to inactivation of CPT via lactone hydrolysis(Figure 9). Although 
CT3 MLNPs delivered more pTRAIL per molecule of CPT (Table 10), they also 
provided more PEI, which could potentially reduce the efficacy of CPT. The CT2 
formulation delivered a ratio of CPT to pTRAIL of approximately 0.03 which is 
smaller than the ratio of CPT to pTRAIL doses used in the death kinetics 
experiments.  
5.4 Analysis of synergism. 
Dose effect curves were then obtained for CT2 MLNPs, CL2 MLNPs, CPT 
NPs, and BT MLNP on inhibiting U87, HCT116, and MDAMB231 cell growth in 
vitro. There was a strong left shift in the dose effect curves of CT2 MLNP when 
compared to both CPT NPs, CL2 MLNPs, and BT MLNPs for all cell lines. The 
CPT Dm was significantly lower when using the CT2 MLNP formulation. 
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Modelling the data using the linearized MEE (Equation 2) resulted in correlation 
coefficients greater than 0.9 for all curves indicating a goodness of fit of the linear 
regression, and validating the use of the Chou-Talalay analysis for assessing 
synergism between CPT and pTRAIL when delivered via MLNPs. The CI values 
were less than one for almost all Fa levels. Specifically, the majority of both 
experiment and theoretical CI values were between 0.3-0.7 for all cell lines which 
suggests a synergistic interaction(Figure 22 and Figure 23). The CPT DRI at Fa50 
ranged from 3.14-7.38 for CPT and 4.66-6.09 for pTRAIL. The actual CPT dose 
along with specific Fa50 DRI and CI values for each cell line are listed in Table 12 
and Table 13. The lower CPT DRI for HCT116 and U87s may be due to the 
increased sensitivity of this cell line to CPT compared to MDAMB231s. 
The in vitro synergy analysis not only supports the efficacy of co-delivering 
CPT and pTRAIL for reducing tumor cell growth, but it also validates the use of 
MLNPs for co-delivery of the two agents. This is the first successful in vitro 
analysis of synergism for a nanoparticle delivery system providing combination 
therapy. The resulting DRI values for the CT2 MLNP formulation suggests that 
we can deliver a dose that is approximately order of magnitude lower via 
combination delivery. This can potentially result in safer treatment regimens 
through decreasing system toxicities. Additionally, certain drugs have lower 
encapsulation efficiencies in PLGA nanoparticles. Combination therapies can 
potentially improve therapeutic efficacy for other cancer chemotherapeutics 
because they decrease the required dose for effectiveness.  
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5.5 Antitumor evaluation of MLNPs in vivo. 
The preliminary in vivo evaluation of the therapeutic efficacy for 
combination gene and small molecule therapy demonstrates a greater antitumor 
effect of CT2 MLNPs when compared to both CL2 MLNPs and BT MLNPs. 
Definitive conclusions cannot me made at this time, as it is still early in the tumor 
growth curve. The therapeutic study is ongoing, and tumor size and mouse 
weight will be monitored for several more days.  
5.6 Conclusion. 
Nanoparticles provide exciting avenues for addressing current obstacles in 
cancer chemotherapy. As discussed, most chemotherapeutic agents have 
inherent risks, and limitations in efficacy. Nanoparticles can provide a stable 
vehicle for targeted delivery in order to reduce systemic toxicities. Further, 
utilizing these vectors for combination, multi-modal therapy allows for minimizing 
drug resistance and improving efficacy. Tumors are highly heterogeneous, and 
so the necessity for personalized medicine and the ability to deliver multi-modal 
therapy is important. It is necessary to design nanocarriers to utilize synergistic 
agents in order to increase their potency, and allow for decreased dosing. 
Although, there have been considerable improvements in particle transfection 
capabilities, their efficiency is much lower than viral vectors. Particles that 
demonstrate high transfection capabilities, including most lipid particles, are both 
toxic and unstable. Additionally, co-delivering small molecules with genetic 
material via nanoparticles has been inefficient. MLNPs show promise in providing 
a delivery vehicle for tunable small molecule encapsulation and release as well 
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as high gene transfection potential. The results support our hypothesis that 
delivering multiple therapeutic agents using MLNPs can provide improved anti-
tumor effects when compared to monotherapy. The in vitro studies showed 
tunable anti-tumor effects of co-delivering TRAIL plasmid and CPT. Additionally, 
co-delivery with MLNPs showed a synergistic inhibition of tumor growth in vitro, 
and preliminary in vivo evaluation of their antitumor effects are promising. Future 
nanoparticle formulations for combination therapies should also be analyzed in 
vitro for synergism prior to in vivo evaluation. The MLNP’s modular, 
multifunctional design provides a robust system for efficiently delivering both 
small molecules and gene therapy, and create an attractive vehicle for 
combination anti-cancer therapies. 
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Figure 1: Relative sizes of nanoparticles compared to common biological 
structures. 
Illustration of nanoparticle size as compared to common biological structures and 
their associated length scale. An electron microscope is needed to visualize 
structures that are submicron in size.  
Figure 2: Hydrolysis of poly(lactic-co-glycolic) acid. 
The chemical structure of poly(lactic-co-glycolic) acid and its hydrolytic 
breakdown into biocompatible metabolites.  
Figure 3: Distribution coefficient of common anti-neoplastic agents. 
The frequency distribution of anti-neoplastic agents by lipophilicity. The 
distribution coefficient (D) is a measure of lipophilicity, and log(D) values greater 
than zero indicate greater solubility in oil rather than water. The majority of 
clinically available anti-neoplastic agents are lipophilic.  
Figure 4: Nanoparticle pharmacokinetics. 
Drug plasma concentrations associated after repeated free drug boluses 
compared to a single nanoparticle dose. Due to rapid bioavailability and 
clearance of free drugs relative to drug encapsulated polymer nanoparticles, 
plasma concentrations (blue line) will oscillate above and below the maximum 
tolerated concentration (MTC) and minimum effective concentration (MEC). 
Plasma drug levels above the MTC will result in systemic toxicity whereas drug 
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levels below the MEC will be ineffective. Drug loaded polymer nanoparticles 
theoretically release drugs via first order rate kinetics resulting in a more stable 
plasma drug level. 
Figure 5: Mechanism for iRGD binding and penetration57. 
The mechanism for internalizing RGD (iRGD) binding and penetration into the 
endothelium of tumor vasculature. The process includes binding of the RGD 
motif to the αvβ3/αvβ5 integrins that are up regulated on tumor endothelial cells. 
The peptide is then cleaved by proteases, which expose the CendK/R element 
allowing for subsequent binding to neuropilin-1 and penetration into the tumor 
tissue.  
Figure 6: Pathways for endocytosis. 
The multiple endocytic pathways and their associated biophysical properties. 
Each pathway has characteristic compartment sizes, molecular players, and 
intracellular fates. Certain targeting moieties can be utilized to target specific 
endocytic pathways, and common examples are provided. AP – antennapedia, 
CDC42 - cell division cycle 42, CLIC-D - dynamin-dependent clathrin-
independent carriers, CLIC-DI - dynamin- and clathrin-independent carriers, ER – 
endoplasmic reticulum, RGD - arginine-glycine-aspartic acid, TAT – 






Figure 7: Barriers to gene therapy. 
The six major barriers for gene delivery. Gene loaded particles need to be stable 
and need to protect their genetic cargo during transport in the circulatory system, 
while ultimately being able to localize at the target tissue (1). After penetrating 
the tissue vasculature, there needs to be efficient uptake of the particle into the 
cell (2). After endocytosis, the particle needs to effectively escape the endosome 
(3) and transfer into the nucleus (4). Once inside the nucleus, the transgene 
needs to persist and maintain adequate transcriptional activity (5). During the 
entire process, these particles will need to evade the host immune response (6). 
CTL – cytotoxic T lymphocyte, L – lysosome, V – vesicle. R – endosomal 
recycling, T – transcytosis. 
Figure 8: Apoptosis signaling cascade. 
The intrinsic and extrinsic regulatory pathways of caspase mediated apoptosis. 
Intrinsic stress, including genetic instability from cytotoxic chemotherapeutics like 
camptothecin (CPT), and extrinsic death receptor signaling can increase 
apoptosis via caspase activation. Activating both pathways can potentially 
overcome resistance due to mutations in TP53. Growth receptor signaling 
decreases caspase activation, and can be a target for anti-neoplastic therapies.  
Figure 9: Reversible hydrolysis of camptothecin. 
Camptothecin can be reversibly hydrolyzed from the active lactone form into the 
inactive carboxylate form. Acidic conditions favor the close lactone form, whereas 
basic conditions favor lactone opening.  
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Figure 10: Surface modification of multi-layered nanoparticles. 
Schematic for the step-by-step fabrication and surface modifications of multi-
layered nanoparticles (MLNPs). A-B. Camptothecin was encapsulated into 
poly(lactic-co-glycolic) (PLGA) nanoparticles. C-D. The PLGA nanoparticles were 
complexed with polyethyleneimine (PEI) which results in a net positive surface 
charge on the MLNPs. E-F. Plasmid DNA was then complexed onto the positive 
surface of the MLNPs. G-H. Another layer of PEI was subsequently complexed 
onto the MLNPs. I-J. A heterobifunctional polyethylene glycol (PEG) linker was 
then conjugated to the outer PEI layer. K-L. Finally, a cell penetrating peptide, 
specifically modified antennapedia, was conjugated to the PEG linker.  
Figure 11: Experimental design for evaluating death kinetics associated 
with camptothecin exposure and TRAIL plasmid transfection. 
The experimental design for determining death kinetics after camptothecin (CPT) 
exposure and TNF related apoptosis inducing ligand plasmid (pTRAIL) 
transfection. Cells (U87, HCT116, and MDAMB231) were seeded in 96 well 
culture plates at 2,500 cells/cm2. All treatment groups were transfected with 
pTRAIL 48 h after seeding, and exposed to CPT 24 h before (-24 h), during (0 h), 
or 24 h after (+24 h) CPT exposure. Treatment controls included no treatment 
(NT), and CPT exposure alone at the respective time points. Treatment groups 





Figure 12: The effect of surface modification on particle size. 
Scanning electron microscopy (SEM) images of multi-layered nanoparticles 
during surface modification. A. Non-modified poly(lactic-co-glycolic) acid (PLGA) 
nanoparticles. B. PLGA nanoparticles with surface polyethyleneimine (PEI) and 
plasmid DNA (PLGA-PD). C. PLGA-PD particles modified with a second layer of 
PEI (PLGA-PDP. D. PLGA-PDP particles modified with a heterobifunctional 
polyethylene glycol (PEG) linker (PLGA-PDP-PEG). E. PLGA-PDP-PEG particles 
conjugated to modified antennapedia (PLGA-PDP-PEG-mAP). F. Dry particle 
diameters measured from SEM images. Figure 12A contains a different length 
scale. 
Figure 13: The effect of surface modifications on particle surface charge 
and polyethyleneimine loading. 
The surface charge and polyethyleneimine (PEI) load of multi-layered 
nanoparticles during surface modification. A. Non-modified poly(lactic-co-glycolic) 
acid (PLGA) nanoparticles. B. PLGA nanoparticles with surface PEI (PLGA-P). 
C. PLGA-P particles complexed with plasmid DNA (PLGA-PD). D. PLGA-PD 
modified with a second layer of PEI (PLGA-PDP). E. PLGA-PDP particles 
modified with a heterobifunctional polyethylene glycol (PEG) linker (PLGA-PDP-
PEG). F. PLGA-PDP-PEG particles surface conjugated with modified 





Figure 14: The effect of surface modifications on particle toxicity. 
Toxicity of multi-layered nanoparticles after surface modification. A. Poly(lactic-
co-glycolic) acid (PLGA) nanoparticles with surface polyethyleneimine (PEI) and 
plasmid DNA (PLGA-PD). B. PLGA-PD particles with a second layer of PEI 
(PLGA-PDP). C. PLGA-PDP particles modified with a heterobifunctional 
polyethylene glycol (PEG) linker attached to modified antennapedia (PLGA-PDP-
PEG-mAP). D. Lipofectamine particles. PLGA-PDP-PEG-mAP particles were 
significantly less toxic than the other particles.  
Figure 15: Particle release profiles. 
Camptothecin (CPT), polyethyleneimine (PEI), and plasmid release from non-
modified nanoparticles and multi-layered nanoparticles (MLNPs). Surface 
modification did not affect CPT release. Approximately 80% of total CPT was 
released in 12-24 h, while approximately 80% of total plasmid was released 
between 24-48 h.  
Figure 16: Population transfection optimization. 
Optimizing multi-layered nanoparticles (MLNPs) for transfecting 293T cells. 
MLNPs were loaded with a plasmid encoding for luciferase. A. The effect of 
surface modification on particle transfection. B. The effect of decreasing the size 
of the polyethylene glycol (PEG) linker, changing the organic solvent during 
fabrication, and encapsulating trans-1,2-cyclohexanediol (TCHD) within the 
poly(lactic-co-glycolic) acid (PLGA) core on particle transfection. C. The effect of 
initial seeding density on particle transfection. EA – ethyl acetate, DCM – 
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dichloromethane, PLGA-PD - PLGA nanoparticles with surface PEI and plasmid 
DNA), PLGA-PDP - PLGA-PD modified with a second layer of PEI, PLGA-PDP-
PEG-mAP - PLGA-PDP particles modified with a heterobifunctional polyethylene 
glycol (PEG) linker attached to modified antennapedia.  
Figure 17: Green fluorescent protein expression after particle transfection. 
Confocal fluorescent imaging of 293T cells transfected with multi-layered 
nanoparticles (MLNPs) or lipofectamine particles carrying plasmid encoding for 
green fluorescent protein (GFP). A-B. 293T cells transfected with MLNPs after 48 
h and 72 h respectively. C-D. 293T cells transfected with lipofectamine after 48 h 
and 72 h respectively.  
Figure 18: Percent cell transfection. 
Fluorescence-activated cell sorting (FACS) of 293T cells transfected with multi-
layered nanoparticles (MLNPs) or lipofectamine particles carrying plasmid 
encoding green fluorescent protein (GFP). Fluorescence measured via the FL1-H 
channel detected transfected cells. After 72 h, approximately 37% of cells were 
transfected by MLNPs and 58% of cells were transfected by lipofectamine.  
Figure 19: Tumor death kinetics relative to camptothecin exposure and 
transfection with plasmid encoding for TNF related apoptosis inducing 
ligand. 
Death kinetics of A. U87, B. HCT116, and C. MDAMB231 cells related to 
camptothecin (CPT) exposure and TNF related apoptosis inducing ligand 
(TRAIL) plasmid transfection. Cells were exposed to CPT 24 h before, during (0 
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h), or 24 h after transfection. Relative growth inhibition was determined by 
normalizing cell viability after combined treatments to cells exposed to CPT only 
at respective time points.  
Figure 20: The effect of multi-layered nanoparticle loading and cell death. 
Cell viability 72 h after exposure to multi-layered nanoparticles (MLNPs) loaded 
with decreasing camptothecin (CPT) relative to TRAIL plasmid (pTRAIL). 
HCT116 cells were exposed to MLNPs loaded with CPT to pTRAIL ratios of 5, 
0.03, and 0.01 (CT1, CT2, and CT3 respectively). Treatment with CT2 MLNP 
resulted in significantly lower cell proliferation.  
Figure 21: Dose Effect curves. 
The fraction affected (Fa), in terms of cell death, related to camptothecin (CPT) 
and TRAIL plasmid (pTRAIL) dosing as delivered by different nanoparticle 
systems. A. Tumor cells were exposed to multi-layered nanoparticles (MLNPs) 
delivering CPT and a plasmid encoding for luciferase (CL2 MLNP), and MLNPs 
delivering CPT and pTRAIL (CT2 MLNPs). B. Tumor cells were exposed to CT2 
MLNPs and poly(lactic-co-glycolic) (PLGA) nanoparticles encapsulating CPT only 
(CPT NPs). C. Tumor cells were exposed to MLNPs containing only pTRAIL (BT 
MLNPs) or CT2 MLNPs. All MLNPs were loaded with the same amount of 





Figure 22: Chou-Talalay synergism analysis of CT2 MLNPs compared to 
CL2 MLNPs and BT MLNPs. 
The Chou-Talalay analysis of the dose effect curves determined in Figure 21. 
Combination index (CI) values for multi-layered nanoparticles (MLNPs) delivering 
CPT and plasmid encoding TNF related apoptosis inducing ligand (pTRAIL) (CT2 
MLNPs), and the CPT and pTRAIL dose-reduction index of CT2 MLNPs relative 
to MLNPs delivering CPT and a plasmid encoding for luciferase (CL2 MLNP) and 
MLNPs containing only pTRAIL (BT MLNPs). The theoretical values were those 
determined by the Chou-Talalay analysis model for all fraction affected (Fa) 
levels, and the experimental values were those determined for actual CT2 MLNP 
doses. All MLNPs were loaded with the same amount of plasmid and the same 
CPT to pTRAIL ratio of 0.03.  
Figure 23: Chou-Talalay synergism analysis of CT2 MLNPs compared to 
CPT NPs and BT MLNPs. 
The Chou-Talalay analysis of the dose effect curves determined in Figure 21. 
Combination index (CI) values for multi-layered nanoparticles (MLNPs) delivering 
CPT and plasmid encoding TNF related apoptosis inducing ligand (pTRAIL) (CT2 
MLNPs), and the CPT and pTRAIL dose-reduction index of CT2 MLNPs relative 
to poly(lactic-co-glycolic) (PLGA) nanoparticles encapsulating CPT only (CPT 
NPs) and MLNPs containing only pTRAIL (BT MLNPs). The theoretical values 
were those determined by the Chou-Talalay analysis model for all fraction 
affected (Fa) levels, and the experimental values were those determined for 
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actual CT2 MLNP doses. All MLNPs were loaded with the same amount of 
plasmid and the same CPT to pTRAIL ratio of 0.03.  
Figure 24: in vivo antitumor effects of MLNPs. 
The tumor growth curve for HCT116 xenografts in mice receiving treatments with 
MLNPs. This is the initial growth response shows a greater inhibition of tumor 
growth for mice receiving CT2 MLNPs and BT MLNPs.  
8 Tables 
Table 1: Hallmarks of cancer pathogenesis and therapeutic implications. 
The cellular and molecular alterations responsible for the multiple hallmarks of 
cancer pathogenesis as described by Hanahan et al7 and related targeted 
therapies. Bax - Bcl-2-associated X, Bcl - B-cell lymphoma, BRCA – breast 
cancer, CCL5/RANTES - Chemokine (C-C motif) ligand 5/ regulated on 
activation, normal T cell expressed and secreted, CCPs - cysteine cathepsin 
proteases, CD4 – cluster of differentiation 4, CSF – colony-stimulating factor, 
CTL - CD8+ cytotoxic T lymphocytes, EMT - epithelial-mesenchymal transition, 
EPH – ephrin type, FGF - fibroblast growth factor, GLUT – glucose transporter, 
HGF – hepatocyte growth factor, HIF – hypoxia-inducible factor, IDH - isocitrate 
dehydrogenase, IL – interleukin, LKB1 – liver kinase B1, MAP – mitogen-
activated protein, MCL – myeloid cell leukemia, MDSCs - myeloid-derived 
suppressor cells, mTOR – mammalian target of rapamycin, NF2 – neurofibromin 
2 (merlin), NK – natural killer, PI3 - Phosphatidylinositide 3, PTEN – phosphatase 
and tensin homolog, RB – retinoblastoma, Robo – roundabout, TGF – 
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transforming growth factor, Th – T helper, Tregs - regulatory T cells, TSP – 
thrombospondin, VEGF – vascular endothelial growth factor, ZEB - Zinc finger E-
box-binding homeobox. 
Table 2: Examples of nanoparticle therapeutics. 
Examples of nanocarriers and specific formulations that are being clinically 
evaluated for treating cancer. PLA – Polylactic acid, tSVPTM – targeted 
Synthetic Vaccine Particle. 
Table 3: Lipophilicity of common anti-neoplastic agents. 
The distribution coefficients (D) of clinically available anti-neoplastic agents 
organized by class.  
Table 4: Methods of gene delivery56,58,78,79,81,82. 
Methods for gene delivery. There are multiple categories of delivery methods for 
genetic material. Specific gene delivery systems within each class, and the 
associated transfection efficiencies and toxicities for each modality are provided. 
I-low, II-medium, III-high, GALA- glutamic acid-alanine-leucine-alanine, KALA- 
lysine-alanine-leucine-alanine, PAMAM-polyamidoamine, PbAE- poly(beta-amino 







Table 5: Strategies for addressing gene delivery barriers via nanoparticles. 
Nanoparticle technology can address the multiple barriers (Figure 7) for gene 
delivery. Common techniques to address the six major barriers are provided. 
NLS – Nuclear localization signal, TCHD - trans-cyclohexane-1,2-diol. 
Table 6: Evaluation of Combination Index values125,126. 
The combination index (CI) values obtained from the Chou-Talalay analysis can 
predict synergistic, additive, or antagonistic interactions. Values less than one 
suggest a synergistic interaction, and values greater than one suggest an 
antagonistic interaction. CI values close to one are indicative of an additive 
response.  
Table 7: Particle characteristics. 
Physical characteristics of multi-layered nanoparticles. Dry and hydrodynamic 
particle diameter as measured by scanning electron micrograph (SEM) and 
dynamic light scattering (Zeta), surface charge, polyethyleneimine (PEI) loading, 
and plasmid loading for each particle formulation are provided.  
Table 8: Camptothecin encapsulation. 
Camptothecin (CPT) encapsulation and loading efficiency for multi-layered 
nanoparticles (MLNPs). MLNPs were initially loaded with 0.1, 0.001, or 0.0001 





Table 9: Camptothecin to TNF related apoptosis inducing ligand ratio. 
The camptothecin (CPT) to TNF related apoptosis inducing ligand (TRAIL) ratios 
for the treatment groups analyzed in the death kinetics experiments (Figure 19).  
Table 10: Camptothecin to TNF related apoptosis inducing ligand ratio for 
multi-layered nanoparticle formulations. 
The camptothecin (CPT) to TNF related apoptosis inducing ligand (TRAIL) 
loading ratios for the multi-layered nanoparticles analyzed in Figure 20. These 
particles are the same formulations analyzed in Table 8.   
Table 11: Goodness of fit of the Chou-Talalay analysis. 
The linear regression coefficients for fitting the dose effect curves (Figure 21) to 
the median effect equation (MEE) transformation (Equation 2). The coefficients 
were greater than 0.90 for all dose effect curves indicating that the MEE is a 
good model. 
Table 12: Combination index, dose-reduction index, and median effect 
dose, for CT2 MLNPs and CL2 MLNPs. 
The combination index (CI), dose-reduction index (DRI), and the median effect 
dose (Dm) for the different nanoparticle formulations. Dm is the dose of CPT 
required to obtain a Fa level of 0.50. Multi-layered nanoparticles (MLNPs) 
delivering camptothecin (CPT) and TNF related apoptosis inducing ligand 
plasmid (CT2 MLNP) were compared to MLNPs delivering CPT and a plasmid 
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encoding for luciferase (CL2 MLNPs). All MLNPs were loaded with the same 
amount of plasmid and the same CPT to pTRAIL ratio of 0.03.  
Table 13: Combination index, dose-reduction index, and median effect dose 
for CT2 MLNPs and CPT NPs. 
The combination index (CI), dose-reduction index (DRI), and the median effect 
dose (Dm) for the different nanoparticle formulations. Dm is the dose of CPT 
required to obtain a Fa level of 0.50. Multi-layered nanoparticles (MLNPs) 
delivering camptothecin (CPT) and TNF related apoptosis inducing ligand 
plasmid (CT2 MLNP) were compared to poly(lactic-co-glycolic) acid 
nanoparticles containing only CPT (CPT NPs). The MLNPs were loaded with a 
CPT to pTRAIL ratio of 0.03. 
